Small Molecule Probes for Photodynamic Therapy (PDT)...Dave, Fioralba, Aaron, Johan and many more...
Transcript of Small Molecule Probes for Photodynamic Therapy (PDT)...Dave, Fioralba, Aaron, Johan and many more...
Small Molecule Probes for Photodynamic Therapy (PDT)
by
Kamalpreet Singh
A thesis submitted in conformity with the requirements for the degree of Master of Science
Department of Chemistry University of Toronto
© Copyright by Kamalpreet Singh 2019
ii
Small molecule probes for photodynamic therapy (PDT)
Kamalpreet Singh
Master of Science
Department of Chemistry
University of Toronto
2019
Abstract
Photodynamic therapy is a clinically approved cancer treatment that utilizes singlet oxygen
generated via a combination of photosensitizer (PS), light and molecular oxygen to kill cells.
Unfortunately, the technique remains under-utilized due to the indiscriminating phototoxicity of
PSs upon irradiation, causing damage to healthy cells alongside cancer cells. Pro-drug derivatives
of pre-existing PSs that are activated by enzymes overexpressed in cancer cells offer a great
solution. Such derivatives are inactive until acted upon by cancer biomarkers, allowing for cancer
targeted cell death. This work highlights the preliminary work in the development of 2 such
activatable PSs, activated by the cancer biomarkers, O6-methylguanine-DNA-methlytransferase
and Nitroreductase. In addition, the development and photophysical characterization of a novel
coumarin based PS is also discussed.
iii
Acknowledgments
I would like to begin by thanking my thesis supervisor and mentor, Dr. Andrew Beharry. Thank
you for giving me the opportunity to work in your lab and helping me grow as a scientist. I hope
to continue using the skills you have given me to make you proud wherever I go.
I would also like to thank Dr. Patrick Gunning for serving as the second reader for this thesis. I am
grateful for your valuable feedback and mentorship in my time of need.
I also want to add a special mention to my family and friends (Angel, Khalid, Aditya, Advait,
Dave, Fioralba, Aaron, Johan and many more not listed here) for their continuous emotional and
moral support. The companionship of these individuals in my first year did not let me feel the
absence of a lab group.
Finally, I would like to thank the people at the Beharry lab. There was never a dull moment
working in the lab, making it feel like home. I would like to especially thank Rita Bodagh for
working on the MGMT protein expression with me and teaching me mammalian culturing. I would
also like to thank Karishma Kailass for conducting the cell imaging for the MGMT project and
Nima Gharibi for measuring the irradiation intensity.
iv
Table of Contents
Acknowledgments ........................................................................................................................ iii
Table of Contents ......................................................................................................................... iv
List of Figures ............................................................................................................................... vi
Chapter 1 Photodynamic Therapy ...............................................................................................1
Cancer .........................................................................................................................................1
What is photodynamic therapy (PDT)?.......................................................................................2
Photosensitizers (PSs) .................................................................................................................4
Activatable Photosensitizers (PSs) ............................................................................................11
Mechanisms of quenching & activatable photosensitizers .......................................................12
Chapter 2 On the road to developing an MGMT activatable Photosensitizer .......................18
O6-Methylguanine DNA Methyltransferase (MGMT) as a PDT target....................................18
Results and discussion ..............................................................................................................22
Future directions & experiments ...............................................................................................31
Materials & methods .................................................................................................................33
Chapter 3 A Hypoxia activatable Photosensitizer ....................................................................44
Nitroreductase (NTR) as a PDT target ......................................................................................44
Results and discussion ..............................................................................................................46
Future directions & experiments ...............................................................................................53
Materials & methods .................................................................................................................54
Chapter 4 3AIC: A Novel Coumarin Based Photosensitizer ...................................................57
Why does the world need a coumarin photosensitizer (PS)? ....................................................57
Results and discussion ..............................................................................................................58
Future directions & experiments ...............................................................................................64
v
Materials & methods .................................................................................................................65
Concluding Remarks ...................................................................................................................69
References .....................................................................................................................................72
Appendix A: NMR & Mass Spectrum of Synthesized Compounds ........................................78
vi
List of Figures
Figure 1.1. A simplified Jablonski diagram for PSs ....................................................................... 2
Figure 1.2. Type I and Type II excitation pathways in PSs ............................................................ 4
Figure 1.3. The biological optical window ..................................................................................... 5
Figure 1.4. Structures of Porphyrin, Chlorin, Bacteriochlorin, and Phthalocyanine ...................... 6
Figure 1.5. Structures of Phenothiazine, xanthene and bodipy scaffolds. ...................................... 7
Figure 1.6. A schematic of the mechanism of action of an activatable PS. .................................. 12
Figure 1.7. A schematic of the mechanism of FRET. ................................................................... 13
Figure 1.8. A schematic of the mechanism of activation of a FRET based activatable PS ......... 14
Figure 1.9. An overview of the quenching due to photoinduced electron transfer (PeT).. .......... 15
Figure 1.10. A schematic of the mechanism of activation of a PeT based activatable PS ........... 16
Figure 1.11. A schematic of the mechanism of activation of a ICT based activatable PS .......... 16
Figure 1.12. A schematic of the mechanism of activation of a caged activatable PS ................. 17
Figure 2.1. A crystal structure of Human MGMT (E.C. 2.1.1.63) .............................................. 18
Figure 2.2. Mechanism of DNA repair by MGMT ....................................................................... 19
Figure 2.3. Expression levels of MGMT in cancer and healthy tissues ....................................... 20
Figure 2.4. Inhibition of MGMT by O6BG & Patrin-2 ................................................................ 20
Figure 2.4. Inhibition of MGMT by O6BG & Patrin-2 ................................................................ 20
Figure 2.5. Modifications of O6BG tolerated by MGMT ............................................................ 20
Figure 2.6. Mechanism of activation of a FRET based MGMT activatable PS .......................... 21
Figure 2.7. Structure of P1 (probe 1) ........................................................................................... 22
vii
Figure 2.8. The synthetic scheme of probe 1 (P1) ........................................................................ 24
Figure 2.9. UV-Visble spectrum of P1 ......................................................................................... 23
Figure 2.10. Fluorescence excitation spectra of P1 ...................................................................... 25
Figure 2.11 Fluorescence emission spectra of P1 ......................................................................... 25
Figure 2.12. A schematic of the mechanism of activation of P1 by MGMT. ............................... 26
Figure 2.13. Fluorescence activatability assay ............................................................................. 26
Figure 2.15. The structure of probe 1 no quencher (P1NQ). ........................................................ 27
Figure 2.16. The synthetic scheme for P1NQ. .............................................................................. 28
Figure 2.17. Initial (test) SDS PAGE assay .................................................................................. 29
Figure 2.18. SDS PAGE assay. .................................................................................................... 30
Figure 2.19. Images from wash out in cellulo assay ..................................................................... 31
Figure 2.20. Future directions ...................................................................................................... 32
Figure 2.21. A proposed PeT based MGMT activatable PS probe (O6BG-PL-3AIC). ................ 33
Figure 3.1.Type I and Type II NTR .............................................................................................. 45
Figure 3.2. Mechanism of the NTR mediated activation of p-NBMB ......................................... 46
Figure 3.3. The synthetic scheme for p-NBMB ............................................................................ 47
Figure 3.4. p-NBMB activatability assay ..................................................................................... 47
Figure 3.5. A kinetic p-NBMB activatability assay (with NTR) .................................................. 48
Figure 3.6. A kinetic p-NBMB activatability assay (without NTR) ............................................. 48
Figure 3.7. Mechanism of activation for the singlet oxygen sensor green (SOS-G) .................... 50
viii
Figure 3.8. p-NBMB singlet oxygen assay (with NTR) ............................................................... 50
Figure 3.9. p-NBMB singlet oxygen assay (without NTR) .......................................................... 50
Figure 3.10. Mechanism of activation of the ROS sensor (DCFH-DA) ....................................... 52
Figure 3.11. p-NBMB ROS assay (without NTR) ....................................................................... 50
Figure 3.12. p-NBMB singlet oxygen assay (with NTR) ............................................................. 50
Figure 4.1. Structure of Eosin ....................................................................................................... 50
Figure 4.2. Structure of Psoralen .................................................................................................. 50
Figure 4.3. Synthetic scheme for the synthesis of 3AIC ............................................................... 59
Figure 4.4. The UV-Visible spectrum of 3AC and 3AIC ............................................................. 59
Figure 4.5 3AIC singlet oxygen assay ......................................................................................... 60
Figure 4.6. 3AC singlet oxygen assay .......................................................................................... 61
Figure 4.7. 3AIC ROS assay ........................................................................................................ 62
Figure 4.8. 3AC ROS assay .......................................................................................................... 63
Figure 4.9. 3AIC Photostability Assay ........................................................................................ 64
Figure 5.1. Structure of the examined enzyme activatable PS probes. ......................................... 69
Figure 5.2. The structure of probe 1 no quencher (P1NQ). .......................................................... 70
Figure 5.3. Structure of the 3AIC. ................................................................................................ 71
Figure S1. 1H-NMR of guanine salt in DMSO-d6. ....................................................................... 78
Figure S2. 1H-NMR of Alkyne O6 Benzyl Guanine in DMSO-d6. .............................................. 79
Figure S3. 1H-NMR of Alkyne O6 Benzyl Guanine N9 Propylamine BHQ2 in DMSO-d6. ........ 80
ix
Figure S4. 1H-NMR of 3-azidopropan-1-ol in CDCl3. ................................................................. 81
Figure S5. 1H-NMR of 3-azido-N-methylpropan-1-amine in CDCl3. Note, the oil was
contaminated with THF and TEA. ................................................................................................ 82
Figure S6. 1H-NMR of CF3 protected 4-methylamine benzyl alcohol in CDCl3. ......................... 83
Figure S7. 1H-NMR of CF3 protected 4-methylamine O6 benzyl guanine in DMSO-d6. ............ 84
Figure S8. 1H-NMR of N-acetylglycine in DMSO-d6. ................................................................ 85
Figure S9. 1H-NMR of 3AIC-Acetate in DMSO-d6. ................................................................... 86
Figure S10. 1H-NMR of 3AIC in CDCl3. ..................................................................................... 87
Figure S12. ESI- mass spectrum of probe 1 (P1) dissolved in methanol. ..................................... 89
Figure S13. ESI+/ESI- mass spectrum of Sarcosine linked pyro A dissolved in methanol. ......... 90
Figure S14. ESI+ mass spectrum of probe 1 no quencher (P1NQ) dissolved in methanol. .......... 91
Figure S15. ESI+ mass spectrum of p-NBMB dissolved in methanol. ......................................... 92
1
Chapter 1 Photodynamic Therapy
Cancer
As the second leading cause of deaths in the world, cancer has become a global health problem1,2.
In fact, the uncontrolled cell division characteristic of the family of more than 100 diseases called
cancer, is the primary cause of deaths in Canada; killing about 1 in 4 Canadians3,4. To treat this
ailment, 3 key traditional treatment regiments - surgery, radiotherapy and chemotherapy - are
commonly employed5,6.
In the surgical approach, the malignant tumor body is excised from the patient using surgical tools7.
Unfortunately due to the local nature of this approach, it is restricted to the treatment of solid
tumors or tumors that are constrained in one area7. Therefore, surgical methods cannot be
efficiently employed in the treatment of disseminated cancer or metastasis, that is the spread of the
tumor from the primary site to distal secondary sites5,7,8. In addition, the cuts produced in the body
from the extraction of the tumor can be painful and slow to heal post-surgery. Consequently,
individuals may opt to utilize an alternative local treatment approach called radiotherapy. Like the
surgical method, radiotherapy also targets localized tumor bodies9. However, instead of utilizing
scalpels, radiotherapy exploits the DNA damaging property of high energy radiation to induce cell
death9. This type of treatment is often utilized in combination with other approaches
(chemotherapy and surgery) to minimize chances of cancer returning9. Unfortunately, much like
surgery, the local nature of radiotherapy also prevents its’ utilization in the issue of metastasis10.
In addition, the exposure of the healthy tissue surrounding the malignant tumor to high energy
radiation during the therapy, often results in severe side effects9. Due to the local restrictions and
adverse effects associated with surgery and radiotherapy, a third type of cancer treatment called
chemotherapy is often called upon5,8. Chemotherapy (“chemo”) is a cancer treatment approach
built around the cytotoxic nature of chemical agents5,8. Due to the lack of local restrictions,
chemotherapy is often utilized for the treatment of disseminated or metastasized cancer5,8.
Although chemo can get around the issue of localized action, anti-cancer drugs frequently lack
structural features which allow them to distinguish between cancer and healthy tissue, leading to
adverse effects in healthy cells alongside tumor cell death11,12. In addition, the success of many
chemo agents is impeded by a loss in potency due to built-in mechanisms in the cells, i.e.
2
resistance8,10. Evidently, the 3 traditional approaches have major limitations and drawbacks and so
it is not surprising that the prognosis for cancer patients remains suboptimal.
What is photodynamic therapy (PDT)?
PDT is a minimally invasive clinically approved cancer treatment approach that relies on the
combined action of 3 individually innocent components - a photosensitizer (PS), light, and
molecular oxygen - to induce cell death13–19. In comparison to traditional treatment regiments, PDT
has several advantages including its non-invasive nature, little to no scarring, ability to treat the
patient in an outpatient setting, ability to utilize repeated doses without the issue of resistance or
exceeding total dose limitations, and fewer adverse effects in comparison to chemotherapy13,14,19.
The process begins with administration of the PS which may be topical or systemic14. Upon
accumulation of the PS in tissues, the target tissue is irradiated with an appropriate wavelength of
light, which results in the excitation of the PS to a singlet excited state. In the singlet excited state,
the excess energy carried by the PS can be dissipated via several processes (Figure 1.1). The excess
energy can be lost via emission of light (fluorescence) or by heat (internal conversion).
Alternatively, the excess energy may also be lost via interactions of the PS dye with its’
surroundings (quenching). The PS can also undergo an electronic rearrangement changing its spin
from the singlet excited state to the triplet excited state. In the triplet-excited state the PS can also
lose the excess energy via emission of light (phosphorescence), heat (internal conversion), or by
various quenching mechanisms.
Figure 1.1. A simplified Jablonski diagram describing the photophysical processes that occur after excitation
of a PS.
3
The excited triplet-state PS can also interact with molecules in its’ surroundings such as molecular
oxygen via non-radiative energy transfer processes, converting ground state triplet oxygen to an
excited singlet state (Figure 1.1)13,17. This type of energy transfer between a PS and molecular
oxygen is referred to as a Type II process (Figure 1.2)13,17. If in a cellular environment, the resultant
reactive form of oxygen can oxidatively damage cells causing cell death. Due to the short half-life
(10-320 nanoseconds) and diffusion (10 to 55 nm) of singlet oxygen in cells, the damage produced
by PSs is often limited to the site of localization, which in combination with intensity of irradiation
and concentration of PS (PDT dose), plays an active role in the mode of cell death13–16,18.
Traditionally it was believed that PDT induced cell death via either apoptosis or necrosis13. PSs
which accumulated in the mitochondria and endoplasmic reticulum (ER) were attributed to cell
death via apoptosis, whereas those which accumulated in the lysosomes or plasma membrane to
necrosis13. However, recent studies have shown that the PDT dose plays a crucial role in the form
of cell death. Photooxidative damage induced by high PDT-dosage in organelles and plasma
membrane are thought to induce ATP depletion thereby initiating necrosis14–16. Whereas, cell
death brought on by low PDT-dosage is thought to be a result of autophagic cell death14–16. In
addition, reactive oxygen species (ROS) production in mitochondria, endoplasmic reticulum (ER),
Golgi apparatus, and even lysosomes are thought to initiate apoptotic cell death14–16.
In addition to the type II processes, PSs can also participate in a Type I process, whereby the PS
undergoes a radical reaction with organic molecules in the cell microenvironment (Figure
1.2)13,16,17. The electron/hydrogen transfer reactions between cellular components and the PS can
result in the generation of a complex mixture of ROS such as superoxide anion radical, hydrogen
peroxide, and hydroxyl radical13,15,16. These ROS species can oxidatively damage the cell, causing
death. Due to the several species involved, type I processes are generally more mechanistically
complex compared to type II processes16. Most PSs are believed to act via type II mechanisms,
with singlet oxygen being the primary cytotoxic agent13,16. Evidently, the properties of the PS play
an integral role in the type of active cytotoxic agent and the mode of cell death. In this regard, the
choice of the appropriate PS is vital in achieving optimal efficacy for treatment.
4
Figure 1.2. A schematic of the two pathways by which a photosensitizer (PS) excited by the approviate
wavelength of light (h), can induce oxidative damage in biomaterials (BM). This image was obtained from
[17].
Photosensitizers (PSs)
As highlighted above, the PS is perhaps the most significant component of PDT. In this context, a
PS refers to a chemical agent or drug, which functions as a mediator between light energy from an
illumination source and molecular oxygen in the cells. To be more specific, the PS is a
chromophore which can absorb light of a particular wavelength and thereafter transmit that excess
light energy on to an oxygen molecule, generating singlet oxygen which can kill cells. The ideal
PS should exhibit minimal dark toxicity, that is it should not be toxic until irradiated with
light14,17,20. The PS should also have good amphilicity17,21. In other words, the PS should have
enough hydrophilicity such that upon systemic administration, the PS can travel to the desired
location with minimal aggregation and degradation but, should also be lipophilic enough to
penetrate the cellular membrane. In addition, it is desirable to have a PS which can be activated by
light energy that falls within the biological optical window (650-900nm) where the absorbance
from endogenous chromophores such as hemoglobin and water is minimal (Figure 1.3)14,17,20,22,23.
Other desirable traits in a PS include high photoactivity (high singlet oxygen quantum yield), high
chemical and photostability and rapid clearance to minimize phototoxic side effects post
treatment14,17,20. The search for such an ideal PS has led to the development of more than 400
chromophores, however, no PS that satisfies all the desired traits has yet been found19.
5
Figure 1.3. The biological optical window (“in vivo imaging”) refers to the region of the visible spectrum
spanning 650-900nm where endogenous chromophores exhibit lowest absorbance. This Figure was obtained
from [22].
Based on their structures, PSs can be divided into two different classes; tetrapyrrole based PSs and
non-tetrapyrrole PSs. The tetrapyrrole PSs family is built around the heterocyclic aromatic ring
structure of 4 different supermolecules: porphyrins, chlorins, bacteriochlorins and an isoindole
derivative called Phthalocyanines (Figure 1.4). Porphyrins are highly attractive chromophores for
PDT, as they absorb in the red (610-630 nm) region of the visible spectrum and exhibit strong
fluorescence upon excitation at the Soret band (~ 400 nm)19. In fact, the porphyrin class was the
first set of compounds used for PDT in the form of a complex porphyrin oligomer mixture called
Photofrin (Table 1.1)20,24. Photofrin was clinically approved for PDT in 199318,20,24. Although still
widely in use, Photofrin suffers from several disadvantages such as prolonged skin sensitivity
(poor clearance) and a small absorbance peak at 630 nm (ε630 ~3000 M-1 cm-1)20,24. Consequently,
other porphyrin-based PSs have now been developed to improve upon these limitations. As shown
in Table 1.1, examples include pyropheophorbide-a, which has a much greater absorbance in the
red region (ε665 ~46000 M-1 cm-1) and protoporphyrin-IX (ε626 ~3000 M-1 cm-1) which exhibits less
skin sensitivity (metabolized in 48 hours)13,20,24.
6
Figure 1.4. Chemical structures of Porphyrin, Chlorin, Bacteriochlorin, and Phthalocyanine macromolecules.
The reduction of one double bond in a pyrrole ring of the porphyrin scaffold leads to another key
class of tetrapyrrole based PSs called Chlorins. These are popular scaffolds for PSs as they have a
high quantum yield of singlet oxygen and a stronger absorption in the red (650-660nm) region
relative to porphyrins coupled with a small bathochromic shift19. Examples of clinically approved
chlorin based PSs include Foscan (m-tetrahydroxyphenylchlorin), Verteporfin (benzoporphyrin)
and chlorin-e6 (Table 1.1)20,24. A further reduction of a double bond in the pyrrole ring of the
chlorin structure leads to another subset of tetrapyrrole PSs called bacteriochlorins
(tetrahydroporphyrin). Due to the double reduction of the pyrrole rings, bacteriochlorins have a
strong absorbance in the 700-800 nm range, a significant bathochromic shift relative to porphyrins
and chlorins19. Consequently, bacteriochlorins offer greater tissue penetration in comparison with
porphyrins and chlorins and as such are an attractive target for utilization in PDT. Examples of
clinically approved bacteriochlorin PSs include Bacteriochlorophyll-a (Table 1.1)13. Another
approach that has been utilized to improve the poor absorbance of porphyrins in the red region of
the visible spectra, is the development synthetic analogues employing isoindole heterocyclic rings
instead of pyrroles. The greater aromatic nature of these scaffolds called Phthalocyanines, resulted
in an incredible increase in the light absorption properties relative to porphyrins, with the scaffolds
having extinction coefficients as great as 200,000 M-1cm-1 in the 650-700 nm range19,20. An
example of a clinically approved Phthalocyanine is aluminum phthalocyanine tetrasulfonate
(Table 1.1)13,20,24. Although, the tetrapyrrole class of PSs exhibit great singlet oxygen quantum
yields and long-wavelength absorbance, many members of this family suffer from poor clearance
leading to prolonged skin sensitivity19,20. In addition, due to the bulky hydrophobic nature of
several members of this class of PSs, they are often prone to aggregation in aqueous environments
hindering systemic administration19,20. Therefore, numerous different non-tetrapyrrole PSs based
7
upon natural and synthetic dyes have been developed and investigated for their photodynamic
activity including hypericin, phenothaizines, xanthenes, and BODIPY.
Hypericin is a naturally occurring chemical that can be extracted from St. John’ wort and is well
known for its ability to make ROS upon excitation in the orange part of the visible spectrum19,20,24.
It has been shown to accumulate in greater amounts in tumor bodies relative to surrounding healthy
tissue and as such is an attractive PS for clinical PDT19. Unfortunately, the extremely hydrophobic
structure of hypericin prevents its utilization as a standalone small molecule PS, requiring a
delivery vehicle such as liposomes24. Clinical investigation of hypericin drug vehicle formulations
to date have been unsuccessful and further investigation is underway20.
Phenothaizines are a family of synthetic dyes derived from the
phenothiazine scaffold (Figure 1.5). Derivatives of this family have
exhibited various biological activities, and as such are actively
employed in the field of medicine and histology. Examples of PSs
derived from the phenothiazine family include methylene blue (MB)
and toluidine blue O (TBO) (Table 1.1)13,19,20,24. These water-soluble
dyes have high singlet oxygen quantum yields and are photoactivated
in the biological optical window (665 nm for MB and 630 nm for
TBO)13,19,20,24. Unfortunately, the positive aspects of MB and TBO
are impeded by their dark toxicity which induces adverse side
effects19. Nevertheless, the clinical potential of these PSs for cancer
PDT is being currently investigated20.
Another group of synthetic dyes that have found their way into the realm of PDT, are the
xanthenes. Much like phenothaizines, the core xanthene scaffold (Figure 1.5) has also found much
utility through derivatization, serving as the core structure in many different fluorophores such as
fluorescein and rhodamine. Further manipulation of the fluorescein structure via introduction of
various heavy atom halogens to promote intersystem crossing has allowed the development of
effective PSs such as Rose Bengal (Table 1.1)13,19,20,24. Rose Bengal is a water-soluble PS which
is photoactivated in the green (560nm) part of the visible spectrum13. It has both a high
fluorescence quantum yield and singlet oxygen quantum yield13. Unfortunately, Rose Bengal
exhibits rapid light induced dehalogenation25. This may be one of the reasons behind why this dye
Figure 1.5. Phenothiazine,
xanthene and bodipy
scaffolds.
8
remains largely at the experimental in vitro stage in terms of its utility as a PS in clinical PDT20.
Addition of iodines, have also been made to BODIPY based fluorophore scaffolds (Table 1.1),
converting them into non-fluorescent highly efficient PSs with near unity singlet oxygen quantum
yields13.
Name Structure λ𝑚𝑎𝑥 (nm) Φ∆
Photofrin
Note: Actual structure is a more complex oligomer with
various ether and ester linkages.
630 0.89
Pyropheophorbide-a
665 0.45
Protoporphyrin-IX
626 0.56
9
Foscan
652 0.43
Verteporfin
686 0.76
Chlorin-e6
660 0.65
Bacteriochlorophyll-
a
770 0.35
10
Aluminum
phthalocyanine
tetrasulfonate
(AlPcS4)
676 0.38
Hypericin
590 0.43
Methylene blue
665
0.55/
0.95
(pH 9)
Toluidine Blue O
630
0.90
(pH 9)
Rose Bengal
560 0.68
11
Iodinated Bodipy
534 ~1
Table 1.1. A list of the various types of PSs in literature with their associated wavelength of photoactivation
(𝛌𝐦𝐚𝐱 ) and singlet oxygen quantum yield (Φ∆). The data presented has been obtained from [13] and [24].
Although there are numerous PSs available in literature, an ideal PS with all the desired
aforementioned traits is yet to be found. It is not surprising that the number of clinically approved
PSs remains low and therefore the utility of photodynamic therapy (PDT) has been limited.
Therefore, improvement in translational progression of PDT requires the development of novel PS
derivatives which exhibit cancer targeting behavior.
Activatable Photosensitizers (PSs)
Activatable PSs are derivatives of traditional PSs which can exist in two different states, an “on”
and “off” state13,26. In the “off” state, the excess energy endowed to the PS during the irradiation
process is taken up by a quenching molecule that is covalently attached, either directly or via a
linker scaffold, to the PS13,26. This quenching effect prevents the occurrence of intersystem
crossing, abolishing the singlet oxygen production by the PS13,26. In other words, the “off” state
PS cannot induce cell death even upon irradiation (Figure 1.6). On the other hand, when in the
“on” state, the PS is structurally modified such that the quencher molecule is no longer covalently
bound, allowing for singlet oxygen production13,26. Put simply, irradiation of the “on” state PS
leads to cell death (Figure 1.6). This “off/on” phenomenon can be exploited to achieve cancer
targeting behavior by linking the activation, that is the transition from the “off” to “on” state due
to quencher PS separation, by the action of a cancer biomarker (Figure 1.6). By connecting the
activation of the PS to the action of small molecules or enzymes that are more abundant/active in
cancer cells relative to their healthy counter parts, more PS will be activated in the cancer cells
compared to the healthy cells. This will translate to greater phototoxicity in cancer cells with
minimal, if any, toxicity in healthy cells.
12
A key component in the development of successful activatable PSs is the use of the appropriate
quenching mechanisms to ensure the PS exhibits minimal singlet oxygen production. In the next
section, a brief survey of the different mechanisms of PS quenching and their application in
development of novel activatable PSs are presented.
Figure 1.6. A schematic of the mechanism of action of an activatable PS. In the off state, the PS cannot produce
singlet oxygen upon irradiation and hence the viability of the cells is not impacted. In the presence of a cancer
biomarker, the PS is activated (turned on) and therefore irradiation of the cells results in production of singlet
oxygen and thereafter cell death.
Mechanisms of quenching & activatable photosensitizers
The generation of singlet oxygen by a PS must proceed via the triplet excited state which in turn
is generated by the electronic rearrangement of the singlet excited state13,26. This excited state
electronic rearrangement occurs via a photophysical process called intersystem crossing (ISC)13,26.
Therefore, photophysical processes which compete and thereby prevent ISC can render the loss of
photosensitization13,26. Such processes include, Förster resonance energy transfer (FRET),
photoinduced electron transfer (PeT), and intramolecular charge transfer (ICT)13,26. In addition to
the photophysical processes, there are also cap and release approaches which employ caged groups
to trap the PS in a non-active form, followed by the subsequent release which results in activation26.
Commonly employed in the field of fluorescent sensors, FRET refers to a photophysical
phenomenon in which the light emitted, called fluorescence, by a donor molecule is transmitted to
an acceptor molecule in close vicinity (less than 10 nm)13,26,27. The acceptor molecule then goes
on to emit the energy in the form of longer wavelength fluorescence. In other words, excitation of
the donor molecule results in emission by the acceptor molecule (Figure 1.7)13,26,27. However, the
acceptor molecule does not always have to be emissive. In some cases, like for activatable PSs, a
non-emissive dark FRET quencher may be utilized13,26–28. These acceptors dyes are very efficient
13
at undergoing internal conversion and therefore release the energy in the form of heat rather than
fluoresence13,26,27. If a PS is near a FRET quencher which absorbs at the emission wavelength of
the PS, the PS cannot undergo ISC and produce singlet oxygen/fluoresence13,26.
Figure 1.7. FRET is based upon a non-radiative transfer of energy from a donor (“D”) fluorophore to an
acceptor (“A”). Excitation of the donor with appropriate wavelength leads to the emission by the acceptor via
some long wavelength fluorescence. This image was obtained from [26] and [27].
This combination of PS and FRET quencher can be utilized to develop an “off” state PS. Since the
FRET quenching effect is strongly dependent on the distance between the FRET pair (PS and
quencher), separation of the two scaffolds results in activation or turning on of the PS13,26–29. By
utilizing the appropriate FRET pair and coupling the separation of the two moieties with the action
of a cancer biomarker, an activatable PS can be prepared. In fact, as shown in Figure 1.8, this
strategy has been employed for the development of protease activatable PSs, where a known
peptide substrate for a protease overexpressed in cancer is modified with a PS (such as
14
pyropheophorbide a) and the appropriate dark quencher (blackhole quencher 3)13,26,29. As
discussed, the PS in this state is unable to produce singlet oxygen. However, upon enzymatic
cleavage of the peptide substrate, the PS and the quencher are separated, leading to liberation of
the active PS capable of producing singlet oxygen and fluoresence13,26,29.
Figure 1.8. A schematic of the mechanism of activation of protease based activatable PSs based on principles
of FRET. The modification of a peptide substrate with a PS and the appropriate non-emissive FRET acceptor
(quencher, “Q”), leads to an off state where singlet oxygen and fluorescence is not produced. Upon enzymatic
cleavage of the peptide, the PS (Donor, “D”) is separated from the FRET quencher, leading to activation and
restoring fluorescence and singlet oxygen production. This image was obtained from [29].
The second photophysical process that can be utilized in quenching applications is photoinduced
electron transfer (PeT). As shown in Figure 1.9, PeT is an electron transfer or redox reaction that
occurs in the excited state26,30. Irradiation of the PS (labelled fluorophore in Figure 1.9) induces an
electronic excitation, moving the electron from the highest occupied molecular orbital (HOMO)
to the lowest unoccupied molecular orbital (LUMO)26,30,31. Normally, this electron will then relax
back to the ground state, emitting fluoresence26,30,31. Alternatively, the PS may also undergo ISC
to the triplet excited state and subsequently produce singlet oxygen26. However, in the presence of
an electron donor, the excess excitation energy brought on by the vacancy in the HOMO of the
PS, can be quenched by the donor species via an electron transfer to the fill the vacancy26,30,31. This
reduction of the PS results in the loss of fluorescence and photosensation properties26,30,31. Note,
the process is fully reversible such that the excited electron is often recovered by the oxidized
electron donor, returning the entire system to the ground state26,30,31.
15
Figure 1.9. A schematic overview of the quenching due to photoinduced electron transfer (PeT). The electron
transfer by the donor group (quencher) to the vacancy produced by photoexcitation of PS in the HOMO serves
to quench the excited state. This image was obtained from [31].
Much like FRET, which requires proximity and spectral overlap between the FRET pair, PeT also
has certain requirements27,28. The redox potentials of the electron donor moiety and the desired PS
must be compatible to allow the electron transfer in the excited state30. In addition, to achieve the
electron transfer, the electronic wave functions of the species must overlap and therefore, the donor
and acceptor moieties must be close together30. Consequently, PeT generally requires much shorter
distances in comparison to FRET. Nonetheless, PeT has been quite useful in the development of
activatable PSs, for example in the case of iodinated BODIPY dyes with aniline moieties32. As
shown in Figure 1.10, in the neutral state, the amine in the aniline moiety is capable of donating
electrons to the BODIPY PS32. This PeT quenching effect inhibits ISC and singlet oxygen
production32. However upon protonation of the amines, the electrons are no longer available for
donation, eliminating the PeT quenching, thereby allowing ISC and production of singlet oxygen32.
In this scenario, the pH dependent protonation of the aniline allows for the modulation of the PeT
quenching effect and as such can be exploited for the development of pH-dependent activatable
PSs.
The third photophysical phenomenon which may be employed in quenching of PSs is
intramolecular charge transfer (ICT)26,30. ICT is also an electron transfer process, however, unlike
PeT which utilizes spatially separated acceptor and donors, ICT occurs within the same system
(i.e. among two different functional groups) or within two systems that are in direct conjugation
with each other26,30. An example of this approach is shown in Figure 1.11. Here, a porphyrin-based
PS is conjugated to an anthracene which acts as an ICT based quencher for the PS, minimizing
singlet oxygen production26,33. This charge transfer induced quenching effect is eliminated upon
16
binding of the positively charged porphyrin to negatively charged DNA, restoring the singlet
oxygen production26,33.
Figure 1.10. A schematic of the PeT based quenching of a pH dependent, BODIPY based activatable PS. In the
neutral state, the amine in the aniline moiety serves as an electron donor and therefore quenches the singlet
oxygen production by the BODIPY PS. Upon protonation of the amine, the electron transfer is eliminated,
abolishing the PeT quenching and restoring the singlet oxygen production. This image was obtained from [32].
Figure 1.11. A schematic of the activation of the ICT quenched porphyrin based activatable PS. The anthracene
moiety directly conjugated to the cationic porphyrin serves as a charge donor, quenching the ISC of the
porphyrin and thereby inhibiting singlet oxygen production. The binding of the positively charged porphyrin
to a piece of negatively charged DNA, diminishes the charge transfer between the anthracene and PS, restoring
singlet oxygen production. This image was obtained from [33].
17
The last approach which can be used to develop activatable PSs is based upon caging or trapping
of the desired PS in a non-active form with molecular scaffolds called cages26. Upon enzymatic
removal of such cages, the active PS is liberated. This strategy has been quite actively employed
in the development of various enzyme activatable PSs utilizing methylene blue34,35. As shown in
Figure 1.12, this approach is based upon caging methylene blue (MB) in a reduced non-active form
called leuco methylene blue (LMB)34,35. In this form, the aromaticity of the PS is interrupted such
that chromophore is no longer able to produce singlet oxygen or fluorescence34,35. Upon enzymatic
removal of the caged scaffold, LMB is released which undergoes rapid spontaneous oxidization
due to the surrounding the environment, producing photoactive MB34,35.
Figure 1.12. A schematic of the caged approach to developing Methylene blue (MB) activatable PSs. The
reduced non-active form of MB called leuco MB is trapped with an enzyme cleavable molecular scaffold or
“cage”. Upon enzymatic removal of the cage, Leuco MB is released which rapidly undergoes spontaneous
oxidation to the photoactive MB.
Clearly there are numerous methods by which the photophysical properties of chromophores may
be modified such that they cannot produce fluorescence and/or singlet oxygen. Unfortunately, as
demonstrated by the existence of only a handful activatable PSs, the concept of enzyme activatable
PSs is yet to be truly embraced in the field of PDT13,26. In addition, the activatable PSs published
in literature have several drawbacks. For example, the FRET based activatable PSs are centered
around peptide substrates, which are known to have poor cellular permeability and therefore have
limited application in vivo13,26. On the other hand, current PeT based activatable PSs are largely
activated in a pH dependent manner rather than enzymes overexpressed in cancer26,32. Much like
the PeT probes, the ICT based activatable PSs are also at a proof of concept level, with no
connection with enzyme activatability26,33. Therefore, the development of novel small molecule-
based enzyme activatable PSs which may surpass such limitations is highly warranted. In this
regard, the next two chapters will discuss the on-going development of two novel enzyme
activatable PS probes. The greater cancer selectivity of the enzyme activatable PSs is expected to
produce minimal if any side effects and therefore increase the clinical utility of PDT.
18
Chapter 2 On the road to developing an MGMT activatable Photosensitizer
O6-Methylguanine DNA Methyltransferase (MGMT) as a PDT target
It is well known that the instructions needed for the survival and proper functioning of living
organisms are stored in a library of biomolecules called DNA. Sometimes this compendium of
biomolecules can become damaged, leading to a loss of information and proper functioning in the
organism, manifesting in the form of diseased states. Such damage can be brought on by alkylation
due to endogenous alkylating agents such as S-adenosylmethionine or exogenous sources such as
tobacco smoke and UV light36–38. The induced alkylation can lead to point mutations which may
serve to activate or suppress cancer related genes or alternatively produce double stranded breaks
in DNA with subsequent apoptotic cell death36–39. One site of alkylation that is especially
mutagenic is the O6 position of guanine, which is known to cause GC to AT mutations and if not
appropriately repaired, induce apoptosis36–39. To cope with such damage, nature has developed
several different repair pathways. One such pathway, is the direct repair pathway which includes
a small DNA repair enzyme (207 amino acid) called O6-methylguanine DNA methyltransferase or
MGMT (E.C. 2.1.1.63) (Figure 2.1)36–38,40.
Figure 2.1. A crystal structure of Human MGMT (E.C. 2.1.1.63). This Figure was obtained from [40].
MGMT is responsible for the repair of methylation at the mutagenic O6 position of guanine in a
single irreversible step37,38,41. Although MGMT shows a preference for O6 methylated guanine,
larger alkyl groups such as ethyl and butyl can also be repaired, albeit less efficiently36–38. It is
worth nothing that MGMT can repair DNA in both condensed and open chromatin forms, working
19
independently without an assortment of proteins/cofactors, characteristic of other DNA repair
pathways such as mismatch repair (MMR)38. To repair the lesions, the alkylated guanine is brought
into the active site of the MGMT, where the methyl group is transferred to a cysteine residue
(cys145 in humans) in an acid catalyzed SN2 like fashion, with final covalent modification of the
enzyme36–38,42. The transfer process is thought to be facilitated by a network of hydrogen bonding
involving water, histidine, glutamic-acid, asparagine, and tyrosine residues in the active site,
increasing the nucleophilicity of the thiolate and the electrophilicity of the alkyl group at O6
position (Figure 2.2)38,42. The resultant alkylated protein is then ubiquitinated and subsequently
degraded by the proteasomal machinary36–38. Since MGMT does not turnover, the repair of O6
adducts is highly dependent on the amount and rate of MGMT produced by the cell36–38.
Figure 2.2. MGMT is a DNA repair enzyme responsible for removal of alkylations at the O6 position of guanine.
The protein utilizes a cysteine residue at its active site as a nucleophile in combination with a hydrogen bonding
network made up of water and several amino acid residues (Tyr, His, Asn, Glu). The alkyl group is transferred
to the cysteine permanently alkylating the protein and restoring native guanine. These images were obtained
from [38] and [42].
Although beneficial in the case of erroneous alkylation of the DNA, the activity of this ubiquitous
enzyme can also serve as a big hinderance in the potency of chemotherapeutics36–38. Many anti-
cancer chemo agents such Temozolomide (TMZ) exert their cytotoxic effect via alkylation at O6
position of guanine43. This is problematic, as the action of MGMT can simply repair these lesions
canceling any potential cytotoxicity. In other words, the action of MGMT serves as a mechanism
of chemo resistance lowering the efficacy of alkylating drugs for cancer treatment36–38,43. This
20
situation is further worsened by the fact that MGMT is overexpressed in several different types of
cancers (Figure 2.3)41.
Figure 2.3. MGMT is a ubiquitous enzyme found in all tissue. It is overexpressed in several different types of
cancers such as breast, brain, colon, lung, rectum and stomach and underexpressed in other such as blood, liver
and testis. This image was obtained from [41].
To resolve this issue, small molecule
inhibitors to block the MGMT mediated
repair have been developed. Two of the most
well-known MGMT inhibitors are O6-benzyl
guanine (O6BG) and O6-(4-bromothenyl)
guanine (Patrin-2) with IC50 values of 200
nM and 4 nM respectively (Figure 2.4)44.
Derivatives of O6 alkylated guanine base,
O6BG and Patrin-2 function as
pseudosubstrates for the enzyme, that is, the
enzyme will transfer the alkyl group at the
O6 position - benzyl for O6BG and 4-
bromothenyl for Patrin-2 - on to itself, losing
function (Figure 2.4)44. O6-BG and Patrin-2
Figure 2.4. O6-BG and Patrin-2 are pseudosubstrates for
MGMT. They act as structural mimics of alkylated
guanine and therefore are repaired by MGMT, resulting
in enzyme alkylation and thereafter inactivation.
21
have been clinically tested and found to induce minimal toxicity when administrated alone45,46.
The established overexpression of MGMT and its mechanism of action
in combination with the availability of small molecule inhibitors, makes
MGMT an attractive target for exploitation in the development of
activatable photosensitizers (PSs). It is well known that addition of
substituents at the para position of the benzyl group and the solvent
exposed N9 and C8 positions of the guanine base in O6 BG are well
tolerated by the enzyme(Figure 2.5)40,47–50. Combining this information
with the mechanism of action of MGMT, O6-BG can be modified with a
PS at the para position of the benzyl group and the appropriate FRET
quencher at the N9 position of the guanine base to develop a FRET
quenched “off” state PS (Figure 2.6). Upon action of MGMT, the PS
conjugated benzyl group will be transferred to the enzyme active site,
thereby separating it from the quencher on the guanine base, eliminating
the FRET quenching effect, thereby turning on the PS. With this design
in mind, probe 1 or P1 was synthesized (Figure 2.7).
Figure 2.6. Modification of O6-BG with a PS at the para position of the benzyl group and the appropriate
FRET quencher at the N9 position allows for the development of a FRET quenched “Off” state PS. Upon action
of MGMT, the benzyl group with the PS is transferred onto the active site of the enzyme resulting in separation
from the quencher group, eliminating FRET quenching and activating/ turning “on” the PS.
Figure 2.5.
Modifications of O6-
BG at the indicated
positions are well
tolerated by MGMT.
22
Figure 2.7. Structure of P1 (probe 1). The commercially available PS, Rose Bengal (λem 575 nm), is utilized in
combination with the FRET quencher black hole quencher 2 (BHQ2) (λabs 560-670 nm).
As shown in Figure 2.7, P1 contains Rose Bengal (λem 575 nm) as the PS and black hole quencher
2 (BHQ2) (λabs 560-670 nm) as the dark FRET quencher13. Rose Bengal was selected due to its
commercial availability, inexpensiveness, good fluorescence and singlet oxygen quantum yields13.
Meanwhile, BHQ2 was selected as its absorption spectrum overlaps with the emission spectrum
of Rose Bengal13.
Results and discussion
Probe 1 (P1) was prepared as shown in Figure 2.8. Rose Bengal (RB) was modified at the carboxyl
position with a 3-azido-N-methylpropan-1-amine linker using HATU mediated amine carboxyl
acid coupling, to obtain RB with an azide functional handle (RB-N3). Next, free guanine base
modified with an O6 benzyl group with an alkyne handle at the para position (compound 2) was
prepared. This scaffold was subsequently modified at the N9 position with the commercially
available propylamine linker to obtain compound 3. The resultant amine handle was utilized to
couple the prepared scaffold (compound 3) with BHQ2-NHS to obtain an alkyne modified O6-
Benzyl guanine with a quencher at the N9 position (compound 4). This scaffold was then finally
23
coupled to the azide functionalized RB PS using copper catalyzed click chemistry to obtain P1
(compound 8). For further details on the synthesis, refer to the materials and methods section
below.
As shown in Figures 2.9-2.11, the λmax, λex, and λem were found to be 565, 568, and 577 nm,
respectively, matching closely with literature13. The probe was then investigated for activatable
behavior using a fluorescence-based assay. As shown in Figure 2.12, in the synthesized form of
P1, the proximity of the FRET quencher (BHQ2) to the fluorescent PS (RB) should yield low
fluorescence. Upon action of MGMT, RB is expected to transfer onto the enzyme, separating it
from the quencher, thereby leading to an increase in fluorescence emission (Figure 2.12).
However, as shown in Figure 2.13, incubation of P1 (58 nM) with MGMT (500 nM) yielded no
change in fluorescence, suggested that P1 was not activated by MGMT.
Figure 2.9. UV-Visble spectrum of P1 (6.3 𝝁M) in basic ethanol. The compound was found to have λmax at
565 nm.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
400 450 500 550 600 650 700
Ab
sorb
ance
Wavelength (nm)
Absorption Spectra
λ max – 565 nm
24
Figure 2.8. The synthetic scheme for the synthesis of probe 1 (P1) labelled as “8”.
25
Figure 2.10. Fluorescence excitation spectra of P1 (58 nM) in buffer containing 70 mM HEPES (pH 7.8), 5mM
EDTA, 1 mM DTT and 1% (v/v) DMSO. The compound was found to have λex at 568 nm.
Figure 2.11 Fluorescence emission spectra of P1 (58 nM) in buffer containing 70 mM HEPES (pH 7.8), 5mM
EDTA, 1 mM DTT and 1% (v/v) DMSO. The compound was found to have λem at 577 nm.
26
Figure 2.12. A schematic of the mechanism of activation of P1 by MGMT.
Figure 2.13. The obtained fluorescence intensity as a function of time for P1 (58 nM) with MGMT (500 nM) in
70 mM HEPES (pH 7.8), 5mM EDTA, 1 mM DTT and 50 µg/mL BSA. The obtained horizontal curve indicated
a lack of activation.
To understand which feature of the probe (the PS or the quencher) was responsible for the lack of
recognition by MGMT, an always-on variant of P1, called P1NQ (Figure 2.15), containing no
modifications at the N9 position of guanine was designed. The choice of PS in P1NQ was revised
such that Pyropheophorbide-a (“Pyro”) would be utilized instead of RB. This revision was
proposed due to the reported poor photostability of RB25, and so, the use of a clinically approved
photostable porphyrin-based PS was adopted. The synthesis of P1NQ was initiated with the
0
200
400
600
800
1000
1200
1400
1600
1800
0 200 400 600 800 1000 1200
Flu
or.
Inte
nsi
ty
Time (sec)
27
modification of the carboxylic acid handle of Pyro with a sarcosine linker (compound 12) (Figure
2.16). The modified pyro was then coupled to the 4-methylamine-O6 benzyl guanine scaffold
(compound 11), to obtain the desired probe (Figure 2.16). Details of synthetic procedures are
provided in the materials and methods section below.
Figure 2.15. The chemical structure of probe 1 no quencher (P1NQ).
Once synthesized, the probe was examined for its ability to covalently label the active site of
MGMT. Since P1NQ is not an activatable probe, an SDS PAGE assay was used to determine if
covalent transfer occurred. In this assay, the enzyme (1 µM) was incubated with the probe (2 µM)
at 37oC overnight, in the dark. The mixture was then combined with an SDS and β-
Mercaptoethanol (BME) containing loading buffer and boiled (90oC) for 10 minutes to induce
denaturation. The resultant mixture was then run through a SDS polyacrylamide gel via
electrophoresis, separating the contents based on their molecular weight. The electrophoresed gel
was then exposed to blue light and the fluorescent response (red light) from Pyro was measured.
If the MGMT was tagged, a fluorescent band matching the molecular weight of the MGMT plus
the transferred group (24.2 kDa) should be observed. As shown in Figure 2.17, this was indeed
the case, indicating the successful transfer of the benzyl group with the sarcosine modified Pyro
to the MGMT active site. To further confirm that the hypothesized tagged MGMT band is indeed
a protein, silver straining was performed resulting in a single band characteristic of the desired
species (Figure 2.17).
28
Figure 2.16. (Top) The synthetic scheme for the synthesis of the necessary precursor molecules for the synthesis
of P1NQ. (Bottom) The synthetic scheme for the synthesis of P1NQ.
29
Figure 2.17. SDS PAGE assay for the investigation of PS transfer to the active site of MGMT. The sample was
prepared via addition of 1 µM MGMT to 2 µM P1NQ in 10 mM PBS (pH 7.4) and 1mM DTT, incubated for
16 hours in the dark at 37oC. The electrophoresed gel was excited with blue light and fluorescent emission was
collected in the red region. The fluorescent image of the gel exhibited two bands, one characteristic of the
combined mass of MGMT and PS (24.2 kDa) and the other characteristic of the free probe (unlabeled). The
presence of protein was confirmed via subsequent silver staining of the gel.
Based on the observed results, MGMT can act upon P1NQ and covalently transfer the desired PS
on to its active site. Unfortunately, a large portion of the probe (“free dye”) was found to unlabeled,
indicating a poor efficiency of transfer (Figure 2.17). To investigate this, another fluorescence SDS
page assay was performed with several different concentrations of P1NQ and MGMT, alongside
controls with only MGMT or P1NQ, and a sample with MGMT pre-treated with inhibitor (O6BG)
(Figure 2.18). As expected, lane A with only MGMT (no P1NQ) showed no fluorescent bands,
while lane F, with only P1NQ (no MGMT), showed only a single fluorescent band characteristic
of the free probe. As previously observed, lanes B-E with both MGMT and P1NQ, exhibited two
fluorescent bands characteristic of tagged MGMT and free P1NQ. In addition, the fluorescence
intensity of the tagged MGMT in these lanes was found to increase as a function of the combined
concentrations of MGMT and P1NQ as indicated by the relative fluorescence intensity (Ir) of the
bands in lane C (0.17) and lane D (0.75) relative to lane D (1.00) (Figure 2.18). Furthermore, the
incubation of MGMT with O6BG prior to the addition of P1NQ (lane B) was found to decrease
the fluorescence intensity of the tagged MGMT band (Ir 0.35 relative to lane E), indicating that
P1NQ is covalently transferred to the active site of the enzyme.
30
Considering the promising results from the fluorescence SDS page assay, in cellulo labeling of
MGMT was examined. As shown in Figure 2.19, P1NQ was added to 2 different cell lines, breast
cancer MCF7 cells with overexpressed MGMT, and MGMT deficient human embryonic kidney
cells, HEK293T. Post incubation and wash, it was expected that the MCF7 cells would exhibit
bright red fluorescence representative of in cellulo MGMT labelling, while the HEK293T cells
would exhibit very minimal or no fluorescence indicating a lack of labeling. Unfortunately, as
shown in Figure 2.19, there was no significant difference in fluorescence in the two cell lines. The
lack of difference was attributed to two factors: i) the hydrophobic nature of pyro and ii) poor
labeling efficiency of MGMT by P1NQ. The hydrophobic nature of pyro was believed to induce
aggregation of the PS and non-specific binding to cellular components upon internalization into
the cell. This non-specific binding effect is hypothesized to impede the adequate washout of P1NQ,
producing significant background fluorescence, leading to similarity in the fluorescent images of
the two cell lines. This situation is further worsened by the poor labeling efficiency of MGMT by
P1NQ, as observed in the fluorescence SDS PAGE assay. This poor labeling may translate to
F E D
C B
A
Tagged
MGMT
Figure 2.18. Fluorescence SDS PAGE assay. Lane A: 1 µM MGMT, lane B: 1 µM MGMT, 0.05 µM O6BG, 1
µM P1NQ, lane C: 0.25 µM MGMT and P1NQ, lane D: 0.5 µM MGMT and P1NQ, lane E: 1 µM MGMT and
P1NQ, lane F: 1 µM P1NQ. Refer to the materials and methods for details.
Free
P1NQ
31
insufficient tagging of the MGMT in MCF7 cells and therefore, the fluorescence signal may not
be as intense as would be expected if the labeling was more efficient. Consequently, the
background signals (fluorescence in HEK293T cells) and the labelled MGMT in MCF7 may be
indistinguishable. To resolve such limitations of P1NQ and ultimately produce a potent activatable
variant, several future modifications are suggested in the section below.
Figure 2.19. Bright field (top) and fluorescent images (bottom) of MCF7 cells (left) with overexpressed MGMT
and HEK293T cells (right) with no MGMT, post 3-hour incubation with 0.85 µM P1NQ and subsequent wash
with 0.01 M PBS (pH 7.4) buffer. Images were taken with a 20X magnification.
Future directions & experiments
As established in the work above, P1NQ is a Pyropheophorbide-a based PS probe, which exhibits
the ability to covalent label native MGMT; a cancer biomarker. As such, P1NQ provides a
foundation from which one may begin the development of a FRET-based MGMT activatable PS
probe. Before one may install a quencher group, it is worth addressing and resolving the limitations
exhibited by P1NQ. It is worth considering the role of linker lengths between the PS and the
32
MGMT recognition scaffold (O6-benzyl guanine), to examine the role of such effects on labeling
efficiency. By utilizing longer linkers, one may potentially decrease any steric effects at the active
site of the enzyme, and thereby improve the labeling efficiency. In addition, it is also worthwhile
to explore the use of different PSs, such that the issue of non-specific binding due to
hydrophobicity of the PS may be eliminated. These two routes may yield a P1NQ derivative, which
could be utilized in washout type assays and serve as a starting point for introducing a quencher
group. Regarding the development of the activatable variant, the length of the linker from the
MGMT recognition scaffold to the quencher should also be investigated. Finally, if the probe is
found to exhibit poor activatability even after all the above-mentioned optimization, then
derivatization of a more potent MGMT inhibitor (e.g. PaTrin-2) should be explored.
Figure 2.20. A schematic of the potential future directions to develop a potent MGMT activatable PS probe.
In addition to developing FRET-based MGMT activatable PS probes, the utilization of the PeT
quenching abilities of guanine base may also be exploited to develop PeT based activatable PS
probes, where no extra quencher molecule is necessary51. To develop such probes, O6BG scaffolds
can be conjugated to a potential PeT compatible PS such as the coumarin based 3AIC (see chapter
four for details on 3AIC) (Figure 2.21)52. The proximity of such PSs to the guanine base may result
in a PeT quenched “off” state of the PS. Once the PS has been separated by the action of MGMT,
the PeT quenching effect may be eliminated yielding an activated PS.
33
Figure 2.21. Proposed structure of a PeT based MGMT activatable PS probe (O6BG-PL-3AIC) using a novel
PS, 3AIC (see chapter four for details on 3AIC).
Materials & methods
General Methods
All reactions were conducted in oven-dried glassware under atmospheric conditions, without the
use of inert gas protection. All reagents for which the synthesis is not provided were purchased
from Sigma Aldrich or Alfa Aesar and used as purchased without further purification. NMR
solvents were purchased from Cambridge isotope laboratories and used without further
purification. Final probe solutions were prepared using high grade DMSO from Thermo Fisher
Scientific. PBS pH 7.4 (1X) buffer was purchased from Thermo Fisher Scientific. NMR data was
collected using a Bruker Avance III 400 MHz spectrometer, with chemical shifts reported in ppm
relative to the residual solvent resonance peaks. Fluorescent spectra were obtained using a
Shimadzu RF-6000 Spectro fluorophotometer while UV-Vis spectra were obtained using a
Shimadzu UV-1800. Fluorescent microscopy was performed using an Olympus IX73. Gel
electrophoresis was performed using the Bio-Rad Mini-PROTEAN® electrophoresis system.
MGMT was purchased from Creative Biomart. All cells were maintained in an atmosphere of
5/95% (v/v) of CO2/air at 37oC. MCF-7 and HEK293T cells were grown in Dulbecco’s
Modification of Eagle’s Medium (DMEM (1X)/high: with 4.5 g/L Glucose, L-Glutamine, without
sodium pyruvate) supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100
μg/mL streptomycin. All cells were plated in 8-chambered wells (Lab-Tek® Chambered #1.0
Borosilicate Coverglass System) at a density of 5×104cells/well one day before imaging.
34
UV-Vis Spectroscopy
Using a 60 𝜇L quartz cuvette, the UV-Vis spectrophotometer was blanked with basic ethanol.
Then, 0.6 𝜇L of a 0.63 mM P1 stock solution (in DMSO) was added to 59.4 𝜇L basic ethanol to
obtain a UV-Vis spectrum of P1 (final concentration 6.3 𝜇M). Note, concentration was determined
using the extinction coefficient (90,000 M-1cm-1) for Rose Bengal in ethanol as reported in
literature13. The procedure was then repeated with a stock solution of P1NQ, using PBS (pH 7.4)
instead of basic ethanol.
Fluorescence Spectroscopy
Excitation spectrum: A sample of P1 (58 nM) at 37oC in buffer containing 70 mM HEPES (pH
7.8), 5mM EDTA, 1 mM DTT and 1% (v/v) DMSO, was excited at various wavelengths (250 to
570 nm) and the resultant fluorescent emission at 577 nm was measured. Note, 3 nm excitation
and emission wavelengths were utilized.
Emission Spectrum: A sample of P1 (58 nM) at 37oC in buffer containing 70 mM HEPES (pH
7.8), 5mM EDTA, 1 mM DTT and 1% (v/v) DMSO, was excited at 568 nm and the fluorescent
emission was measured in the 577-640 nm (Figure 2.11). Note, 3 nm excitation and emission
wavelengths were utilized.
Fluorescence Activatability Assay: A sample of P1 (58 nM) at 37oC in buffer containing 70 mM
HEPES (pH 7.8), 5mM EDTA, 1 mM DTT and 1% (v/v) DMSO was excited at 568 nm and the
resultant fluorescent emission at 577 nm was measured as a function of time. After 5 minutes of
incubation, MGMT (0.6 μM) was added to the sample and the fluoresence intensity was monitored.
In cases where no change was observed, the measurements were performed for atleast 20 minutes.
Note, 3 nm excitation and emission wavelengths were utilized.
SDS PAGE
Casting SDS-PAGE Gels: The separating gel was prepared as follows. 4.1 mL DDI water, 3.3
mL acrylamide (37.5%), 2.5 mL Tris-HCl (1.5 M, pH 8.8), 0.10 mL SDS (10% by volume) were
added to a 50 mL falcon tube and the mixture was briefly vortexed. Then, 0.01 mL TEMED
followed by 0.03 mL APS (10%) was added to the falcon tube and the mixture was briefly
vortexed. The contents were uniformly poured between two glass spacer plates clamped onto the
35
Mini-PROTEAN® tetra cell casting stand, until the solution volume was about 1 cm from the top.
The apparatus was allowed to sit for 30 minutes to allow solidification of the gel matrix. In the
meantime, the stacking gel was prepared as follows. 6.1 mL DDI water, 1.3 mL acrylamide
(37.5%), 2.5 mL Tris-HCl (0.5 M, pH 6.8), 0.10 mL SDS (10% by volume) were added to a 50
mL falcon tube and the mixture was briefly vortexed. Then, 0.01 mL TEMED followed by 0.01
mL APS (10%) was added to the falcon tube and the mixture was briefly vortexed. Once the 30-
minute incubation time was complete, the stacking gel matrix was poured between the two glass
spacer plates until the solvent reached the top of the plates. Then, the comb was carefully inserted
between the spacer plates and gel was allowed to solidify for 30 minutes. Upon solidification, the
gel plates were wrapped in damp paper towels and stored at 4oC for up to 1 week.
The Assay: 10 uL samples were prepared in 1.5 mL centrifuge tubes with the appropriate
components for each lane (see table below). The sample tubes were wrapped in foil and incubated
in a 37oC water bath for overnight. Note, for the inhibitor lane, MGMT and O6BG were first
incubated for 2 hours prior to addition of P1NQ. Then, the tubes were briefly centrifuged and 10.0
uL 2X SDS loading buffer (62.5 mM Tris-HCl pH 6.8, 25% glycerol and 2% SDS, 5% BME) was
added to each sample tube. The samples were then incubated at 90oC for 10 minutes and 10 uL of
each sample was loaded on to the SDS-PAGE gel. Note, 7.5 uL of the ladder was used. The gel
electrophoresis was run at a constant 250 volts for about 30 minutes. The gel was then imaged via
excitation in the blue region and the emission measurement in the red region.
Lane Component (Amounts)
A DTT (1 mM), MGMT (1 µM), PBS
B
DTT (1 mM), MGMT (1 µM), O6BG (50 µM) PBS – 2 hours at 37oC. Then P1NQ (1
µM)
C DTT (1 mM), MGMT (250 nM), P1NQ (250 nM), PBS
D DTT (1 mM), MGMT (500 nM), P1NQ (500 nM), PBS
E DTT (1 mM), MGMT (1 µM), P1NQ (1 µM), PBS
F DTT (1 mM), P1NQ (1 µM), PBS
Refer to Figure 2.18 for the gel.
36
In cellulo labeling
Cells were incubated with 0.85 𝜇M P1NQ for 3 hours in Opti-MEM. They were then washed
with 250 uL PBS 3 times before being imaged in OPTI-MEM.
Synthesis (Refer to Figure 2.8 and 2.16 for full schemes)
Guanine Salt (1): Guanine salt was synthesized based on literature53 using DMF instead of DMSO
as the solvent. Under argon, 1.30 grams (7.6 mmol) of 2-Amino-6-chloropurine (chloroguanine)
was added to 40 mL anhydrous DMF and stirred at 40oC for 30 minutes. The obtained clear yellow
solution was allowed to sit at room temperature for 10 minutes. Then, 5 mL (47 mmol) of 1-
methylpyrrolidine was added and the mixture was allowed to stir at room temperature for 3 days.
After 3 days, a yellow solution with a white precipitate was obtained. 6 mL acetone was added to
the solution to complete the precipitation. The precipitate was isolated via vacuum filtration,
washed with acetone and air dried to obtain the desired product as a white solid (1.67 g (6.55
mmol), yield 86.8%). 1HNMR (400 MHz DMSO-d6): 2.06 (m, 2H), 2.25 (m, 2H), 3.64 (s, 3H),
3.94 (m, 2H), 4.59 (m, 2H), 7.11 (s, 2H), 8.34 (s, 1H), 13.30 (bs, 1H). See appendix A for the
spectra.
37
Alkyne O6 Benzyl Guanine (2): Under argon, 302 mg (2.2 mmol) of 4-ethynylbenzyl alcohol was
added to 9 mL anhydrous DMF and stirred at room temperature for 2 minutes to obtain a clear
yellow solution. Then, 514 mg (4.4 mmol) of potassium tert-butoxide was added, resulting in a
dark red/maroon solution. Next, 300 mg (1.2 mmol) of guanine salt (1) was added, and the mixture
was stirred at room temperature for 3 hours. The solvent was removed in vacuo. The sample was
then dry loaded on to a column and further purified via flash chromatography (100%
dichloromethane to 95% dichloromethane with 5% methanol) to obtain the desired product as a
yellow solid (237 mg (0.893 mmol), yield 75.7%). 1HNMR (400 MHz DMSO-d6): 4.20 (s, 1H),
5.50 (s, 2H), 6.30 (s, 2H), 7.50 (s, 4H), 7.81 (s, 1H), 12.43 (s, 1H). See appendix A for the spectra.
Alkyne O6 Benzyl Guanine N9 Propylamine (3): Under argon, 17 mg (0.06 mmol) of alkyne O6
benzyl guanine (2) was added to 2.65 mL anhydrous DMF and stirred at room temperature for 5
minutes. Then, 4 mg (0.1 mmol) of sodium hydride (60 % dispersion in mineral oil) was added to
the clear yellow solution to obtained orange/red solution. The mixture was stirred for about 5
minutes and then 14 mg (0.06 mmol) of 3-bromopropylamine hydrobromide was added. The
solution was stirred at room temperature for 3 hours, while monitoring the reaction with TLC (90%
ethyl acetate with 10% methanol) and ninhydrin staining. After 3 hours, the reactant was fully
consumed, and the reaction was assumed to be completed. The crude yellow oil was used without
any further purification. See appendix A for the spectra.
38
Alkyne O6 Benzyl Guanine N9 Propylamine BHQ2 (4): Under argon, 3 mg (0.006 mmol) of
blackhole quencher NHS (BHQ2-NHS) was added to 150 𝜇L anhydrous DMF and stirred room at
temperature for 2 minutes. Then, 1.8 mg (0.006 mmol) of Alkyne O6 Benzyl Guanine N9
Propylamine (3) and 4 𝜇L (0.03 mmol) of triethylamine were added to the purple solution. The
reaction was stirred for 24 hours at 40oC. The solvent was removed in vacuo and the obtained
crude product was purified via flash chromatography (100% ethyl acetate to 80% ethyl acetate
with 20% methanol) to obtain the desired product as a purple solid (2.90 mg (0.005 mmol), yield
65.5%). 1HNMR (400 MHz DMSO-d6): 1.81 (m, 2H), 1.89 (m, 2H), 2.18 (m, 2H), 2.68 (m, 2H),
3.07 (s, 6H), 3.95 (s, 4H), 4.01 (s, 6H), 4.20 (s, 1H), 5.50 (s, 2H), 6.46 (s, 2H), 6.89 (d, 2H, J =
9.35 Hz), 7.39 (s, 1H), 7.46 (s, 1H), 7.50 (s, 4H), 7.82 (d, 2H, J = 9.20 Hz), 7.90 (s, 1H), 8.08 (d,
2H, J = 8.85 Hz), 8.45 (d, 2H, J = 9.20 Hz) MS (ESI+) calculated for [M+H]+: 811.34 Da, Found
811.44 Da. See appendix A for the spectra.
3-azidopropan-1-ol (5): 3-azidopropan-1-ol (5) was prepared according to literature54. 28 mg
(0.17 mmol) of potassium iodide was added to 5 mL deionized water and stirred at room
temperature for 5 minutes. Then 1.44 grams (22.1 mmol) of sodium azide and 792 mg (8.37 mmol)
39
of 3-chloro-1-propanol were added. The mixture was refluxed (100oC) for 22 hours. The mixture
was then cooled to room temperature and extracted with diethyl ether (3x12.5 mL). The organic
layers were combined and washed with brine. The organic phase was dried with sodium sulfate
and the solvent was removed in vacuo to obtain the desired product as a clear oil (202 mg (1.99
mmol), yield 23.9%). 1HNMR (400 MHz DMSO-d6): 1.61 (t, 1H), 1.83 (p, 2H), 3.45 (t, 2H), 3.76
(q, 2H). See appendix A for the spectra.
3-azido-N-methylpropan-1-amine (6): 3-azido-N-methylpropan-1-amine (6) was prepared
according to literature54. To a sample of 190 mg (1.88 mmol) of 3-azidopropan-1-ol (5) in 7.5 mL
anhydrous dichloromethane on ice, 0.8 mL (5.5 mmol) triethylamine was added. Then, 0.25 mL
(3.23 mmol) of methanesulfonyl chloride was slowly added to the mixture and stirred for 5 minutes
at 0oC. The solution was stirred for an additional 20 minutes at room temperature and thereafter
the solvent was removed in vacuo. The obtained crude product was dissolved in 15 mL anhydrous
tetrahydrofuran (THF), 75 𝜇L (0.6 mmol) of triethylamine and 3.8 mL (43.8 mmol) of
methylamine (40% in water). The solution was refluxed for 20 hours at 65oC. The solution was
then distilled with a distillation bridge at 90oC at ambient pressure. The obtained distillate was
concentrated in vacuo to obtain the desired product as a faint yellow oil (80 mg (0.7 mmol), yield
37.3%). 1HNMR (400 MHz DMSO-d6): 1.72 (m, 2H), 2.38 (s, 3H), 2.62 (t, 2H), 3.32 (t, 2H). See
appendix A for the spectra.
RB-N3 (7): Under argon, 24 mg (0.02 mmol) of Rose Bengal was added to 1.5 mL anhydrous
DMF and stirred 0oC for 2 minutes. Then, 0.01 mL (0.07 mmol) of triethylamine and 10 mg (0.03
mmol) of HATU were added to the reaction mixture and stirred at 0oC for 5 minutes. Finally, 10
mg (0.03 mmol) of 3-azido-N-methylpropan-1-amine (6) was added to the red solution and the
40
mixture was stirred at 0oC for 2 hours. The mixture was then stirred overnight at 40oC. The solvent
was removed in vacuo and the obtained crude product was purified via flash chromatography
(ethyl acetate with 10% methanol) to obtain the desired product as a red powder (15 mg (0.014
mmol), yield 60.9%). MS (ESI-) calculated for [M-H]-: 1068.57 Da, Found 1068.79 Da. See
appendix A for the spectra.
P1 (8): A stock solution of copper (I) iodide was prepared by combining a solution (25 mg – 0.100
mmol in 1 mL DDI water) of copper (II) sulfate pentahydrate and sodium ascorbate (25 mg – 0.126
mmol in 1 mL DDI water). Then, 2.9 mg (0.004 mmol) of RB-N3 (7) was added to 160 𝜇L
anhydrous acetonitrile. Next, 0.5 mL of the copper (I) iodide stock solution was added to the
mixture and stirred at 40oC overnight. The solvent was removed in vacuo and the crude product
was subsequently purified via flash chromatography (ethyl acetate with 10% methanol to ethyl
acetate with 15% methanol and 2% acetic acid) to obtain the desired product as a purple powder
(6.00 mg (0.003 mmol), yield 89.1%). MS (ESI-) calculated for [M-H]-: 1879.67 Da, Found
1879.80 Da. See appendix A for the spectra.
CF3 Protected 4-Methylamine Benzyl Alcohol (9): CF3 Protected 4-Methylamine Benzyl
alcohol was prepared according to literature55. Under argon, 1 gram (7.35 mmol) of 4-methylamine
benzyl alcohol was added to a round bottom flask with 9 mL anhydrous methanol and 0.9 mL
41
(6.45 mmol) of triethylamine. Next, 1 mL (9.65 mmol) of ethyl trifluoroacetate was slowly added
to the round bottom flask and the reaction was stirred at room temperature for 1.5 hours. Then, the
solvent was removed in vacuo and the obtained crude product was purified via flash
chromatography (2:1 ethyl acetate to hexane) to obtain the desired product as a white powder (1.55
g, (6.65 mmol) yield 90 %). 1HNMR (400 MHz CDCl3): 1.67 (t, 1H), 4.54 (d, 2H, J = 6.21 Hz),
4.72 (d, 2H, J = 4.48 Hz), 6.52 (bs, 1H), 7.34 (d, 4H, J = 26.65 Hz). See appendix A for spectra.
CF3 Protected 4-Methylamine O6 Benzyl Guanine (10): Under argon, 356 mg (1.53 mmol) of
compound 9 was added to a round bottom flask with 7.5 mL anhydrous DMF and stirred at room
temperature for 2 minutes to obtain a yellow solution. Then, 694 mg (6 mmol) of potassium tert-
butoxide was added resulting in a dark red/maroon solution. Next, 205 mg (0.81 mmol) of guanine
salt (compound 1) was added, and the mixture was stirred at room temperature for 3 hours. The
solvent was removed in vacuo. The sample was then dry loaded on to a column and further purified
via flash chromatography (100% dichloromethane to 95% dichloromethane with 5% methanol) to
obtain the desired product as a yellow solid (161 mg (0.81 mmol), yield 54.7%).1HNMR (400
MHz DMSO-d6): 4.40 (d, 2H, J = 6.38 Hz), 5.46 (s, 2H), 6.28 (s, 2H), 7.31 (d, 2H, J = 7.58 Hz),
7.48 (d, 2H, J = 8.71 Hz), 7.80 (s, 1H), 10.00 (s, 1H), 12.40 (s, 1H). See appendix A for the
spectra.
4-Methylamine O6 Benzyl Guanine (11): Under argon, 80 mg (0.218 mmol) of compound 10
was added to a round bottom flask with 4 mL anhydrous methanol and stirred at 60oC until a clear
solution was obtained. Then, 2 mL (33.1 mmol) ammonia solution (32% in water) was added to
42
the solution and the mixture was stirred at 40oC for 3 hours. The reaction completion was
monitored with a TLC accompanied by ninhydrin staining (8:2, DCM/MeOH). The solvent was
removed in vacuo and the crude product was used without further purification.
Sarcosine Linked Pyro A (12): Under argon, 5.4 mg (0.010 mmol) of Pyropheophorbide A was
added to 0.5 mL anhydrous DMF and stirred at 0oC for 2 minutes. Then, 0.05 mL (0.355 mmol)
of triethylamine and 4.6 mg (0.012 mmol) of HATU were added to the reaction mixture and stirred
at 0oC for 5 minutes. Finally, 1 mg (0.011 mmol) of sarcosine was added to the green solution and
the mixture was stirred at 0oC for 2 hours. The mixture was then stirred overnight at 40oC. The
solvent was removed in vacuo and the obtained crude product was used without any further
purification. MS (ESI-) calculated for [M-H]-: 604.74, Found 604.56. MS (ESI+) calculated for
[M+H]+: 606.74 Da, Found 606.54 Da. See appendix A for the spectra.
P1NQ (13): Under argon, 5 mg (0.008 mmol) of compound 12 was added to 0.5 mL anhydrous
DMF and stirred at 0oC for 2 minutes. Then, 0.1 mL (0.355 mmol) of triethylamine and 3.7 mg
(0.01 mmol) of HATU were added to the reaction mixture and stirred at 0oC for 5 minutes. Finally,
43
2.5 mg (0.01 mmol) of compound 12 was added to the green solution and the mixture was stirred
at 0oC for 2 hours. The mixture was then stirred overnight at 40oC. The solvent was removed in
vacuo and the obtained crude product was purified via HPLC (H2O with 0.1% TFA and MeOH
with 0.1% TFA). MS (ESI+) calculated for [M+H]+: 858.41 Da, Found 858.73 Da. See appendix
A for the spectra.
44
Chapter 3 A Hypoxia activatable Photosensitizer
Nitroreductase (NTR) as a PDT target
One of the most well-known characteristics of cancer is rapid, uncontrolled cell division. To
achieve such aberrant growth, the tumor body needs an active supply of nutrients and oxygen.
However, such supply is not always available since tumor growth often exceeds the development
of surrounding vasculature, leading to pockets of low oxygen or hypoxia56,57. These hypoxic zones
lower the effectiveness of chemotherapy by inhibiting the creation of oxygen-based radicals that
are key in inducing cell death via DNA damage56,57. The absence of the appropriate vasculature in
such regions also prevents the adequate delivery of anticancer agents and hence lowers their
potency56,57. Furthermore, hypoxia promotes metastic behavior in cancer cells via loss of adhesion
molecules such as E-cadherin and as a result, decreases the efficacy of surgical treatment56–58.
Fortunately, the aberrant growth, characteristic of tumor bodies, and the resultant hypoxia are
unique to cancer cells, that is, they do not occur under physiological conditions in healthy cells57.
Therefore, the hypoxic microenvironment is an exclusive feature of cancer cells that may be
exploited to gain selective treatment. The lack of oxygen in the tumor body results in a much more
reducing environment compared to healthy cells due to the upregulation of several different types
of reductase enzymes56,57,59. One such family of reductases that are known to be upregulated in
hypoxia and therefore serve as an important cancer biomarker, is Nitroreductase (NTR)34,59,60.
NTR is a family of flavin enzymes, responsible for the reduction of nitro groups, especially
nitroarenes, to their amino counterparts34,59–61. Based on their mechanism of action, the NTR
family can be split into two different groups; type I and type II. The type I NTR (oxygen-insensitive
NTR), reduce the nitro group to the nitroso counterpart via a direct 2 electron transfer (Figure
3.1)60. The resultant nitroso compound is then further reduced to a hydroxylamine and finally the
amine counterparts with the aid of a 2-electron donor, reduced nicotinamide adenine dinucleotide
(NADH) (Figure 3.1)60. On the other hand, type II NTR (oxygen-sensitive NTR) covert the nitro
group to the nitroso counterpart via 2 separate single electron transfer steps, proceeding through
the formation of a nitro anion radical (Figure 3.1)60. Much like the type I NTR mechanism, the
nitroso compound can be further reduced to the hydroxylamine and then the amine with the use of
NADH (Figure 3.1)60. However, in the case of type II NTR this complete reduction is only possible
in a hypoxic environment, since the presence of oxygen leads to the quenching of the nitro anion
45
radical via an electron transfer, reverting the compound back to the nitro form and producing
superoxide anion radicals60.
Figure 3.1. Mechanism of action for the reduction of nitro groups by type I and type II Nitroreductase (NTR).
This image was obtained from [60].
This hypoxia driven conversion of an electron withdrawing group to an electron donor has been
exploited in the development of bio-reductive prodrugs57 and type II NTR activatable
fluorescencent chemosensors for cancer detection59. Unfortunately, the utility of this cancer
biomarker for development of an activatable PS probe is yet to be realized. One possible reason
for this is the misconception that photodynamic therapy (PDT) cannot occur in a hypoxic
environment. While it is true that oxygen is needed to produce the active cytotoxic agent, singlet
oxygen, PDT does not necessarily need ambient concentrations (20%) of oxygen. In fact, PDT has
been shown to work just as efficiently at about 5% oxygen, or under mild hypoxia relative to
normoxia (20%)62. This principle was demonstrated in recent work by the Urano group who
developed a mild hypoxia activatable PS probe based upon the reductive action of an enzyme
overexpressed in hypoxia, Azoreductase63. Based upon on their work, it was proposed that NTR
may also be potentially utilized in an analogous fashion to develop a mild hypoxia, NTR
activatable PS. In designing such a probe, it was found that a methylene blue (MB) based NTR
activatable probe, p-NBMB, had already been developed by the Jo group (Figure 3.2)34. The group
utilized a caging technique to trap the MB in a non-photoactive leuco state by modifying the imine
with an NTR removable scaffold, such that, the aromaticity of the chromophore was lost (Figure
3.2)34. Upon reduction of the nitro group at the para position of the benzyl carbamate scaffold to
46
the amine counterpart, a spontaneous 1,6-rearrangement was triggered, resulting in the elimination
of the cage scaffold and the liberation of the photoactive MB (Figure 3.2)34.
Figure 3.2. Mechanism of the NTR mediated activation of p-NBMB. NTR transfers a single electron to the nitro
group to yield a nitro anion radical. Under hypoxic conditions, NTR may transfer a second electron and with
subsequent aid from NAD(P)H, reduce the nitro anion radical to the amine counterpart. The amine scaffold
then undergoes a 1,6-rearrangement to self-eliminate and liberate the leuco methylene blue which is
spontaneously oxidized by the molecular oxygen to the photoactive MB variant. This image was obtained from
[34].
However, p-NBMB was presented as a fluorescent chemosensor for NTR detection in anaerobic
bacteria and not as an activatable PS34. Thus, we sought out to determine whether p-NBMB could
be used for PDT applications.
Results and discussion
p-NBMB, was synthesized as described by Jo and associates (Figure 3.3)34. The first step of the
synthesis involved the reduction of the photoactive methylene blue (MB) to the non-photoactive
leuco MB derivative using the strong reductant, sodium dithionite in a water-toluene mixture.
Upon reduction, the organic phase was combined with the enzyme trigger group to yield the
desired caged probe. For details on the synthesis, refer to the materials and methods section below.
47
Figure 3.3. The synthetic scheme for the synthesis of p-NBMB as described by Jo and associates34.
Once the probe was synthesized, a UV-Visible spectroscopy-based assay was performed to
examine enzyme induced activatability. As shown in Figure 3.4 (red curve), the UV-Visible
spectrum of p-NBMB in PBS with NADH at 37oC, lacked the absorbance peak at 667 nm
characteristic of the photoactive MB. However, upon addition of Nitroreductase (NTR), an
increase in absorbance at 667 nm was observed within 5 minutes, with a plateau occurring at 1
hour (Figure 3.4 – blue curve). Based upon this data, it appeared NTR was capable of activating
p-NBMB to the photoactive form (MB) as reported by Jo and associates34.
Figure 3.4. Activatability assay using UV-Visible spectroscopy. Leuco MB probe (p-NBMB) (1.7 𝛍𝐌) with 0.1
mM NADH, exhibited no absorbance at 667 nm in the absence of NTR (red curve). After an hour incubation
with NTR (280 n𝐌) an absorbance peak at 667 nm was observed (blue curve).
48
A UV-Visible kinetic assay was also performed to confirm the time taken for the complete
activation of p-NBMB. As shown in Figure 3.5, consistent with the first activatability assay (Figure
3.4), it took about 1 hour to achieve a final fold change of approximately 11-fold. A control assay
was also performed in the absence of the NTR (Figure 3.6) to ensure the activation was driven by
the enzyme. As shown in Figure 3.6, an increase in absorbance at 667 nm was found to occur in
the absence of the NTR as well. However, measurement of the rates of increase in absorbance at
667 nm showed that the increase in the absence of NTR (1.45X10-5 Au/sec) was 10-fold slower
than in the presence of NTR (1.86X10-4 Au/sec). As such, NTR was responsible for the removal
of the cage group resulting in the liberation of the photoactive MB.
Figure 3.5. Measurement of the change in absorbance at 667 nm as a function of time for p-NBMB (1.7 𝛍𝐌) in
PBS with 0.1 mM NADH and 280 n𝐌 NTR. A plateau was observed after approximately 1 hour of incubation
at 37oC.
49
Figure 3.6. Measurement of the change in absorbance at 667 nm as a function of time for p-NBMB (1.7 𝛍𝐌)
in PBS with 0.1 mM NADH (no NTR).
Once the liberation of the photoactive MB from p-NBMB by NTR was confirmed, an investigation
of the NTR induced generation of singlet oxygen by p-NBMB was performed via a fluorescence
assay based using the singlet oxygen sensor green (SOS-G)64. As shown in Figure 3.7, SOS-G
features a chlorinated fluorescein moiety covalently attached to a methyl anthracene (MA)
scaffold. In this form, the MA acts as a quencher for fluorescein64. However, when singlet oxygen
is generated, the MA scaffold is oxidized, forming an endoperoxide such that the quenching of the
fluorescein is diminished, resulting in an increase in fluoresence64. If singlet oxygen generation by
p-NBMB is NTR activatable, an increase in fluorescence emission from SOS-G (λem – 525 nm)
should only be observed upon irradiation of the p-NBMB sample in the presence of NTR. As
shown in Figure 3.8, irradiation of the p-NBMB containing SOS-G sample without NTR did not
induce an increase in fluorescence, indicating the inability of the caged MB to produce singlet
50
oxygen. Meanwhile, a 1.5-hour incubation of the sample with NTR, with subsequent irradiation
of the sample yielded a 1.5-fold increase in fluorescence indicative of singlet oxygen production
(Figure 3.9).
Figure 3.8. Fluorescence emission of SOS-G (1 μM) in a sample of 5 μM p-NBMB, 0.1 mM NADH in 50%
PBS/D2O mixture with 1% DMSO, without irradiation (red curve) and with 5 minutes irradiation (blue curve)
at 625 nm (2.6 mW).
Figure 3.7. A schematic of the mechanism of activation for the singlet oxygen sensor green (SOS-G). The
sensor is weakly fluorescent due to electronic quenching of the fluorescein fluorophore by methyl
anthracene (MA). The quenching is diminished upon oxidation of the MA scaffold by singlet oxygen,
leading to an increase in fluorescence. This Figure was obtained from [64].
550 600 6500
20
40
60
80
Singlet Oxygen Assay
Wavelength
Flu
ore
sen
ce I
nte
nsi
ty
NTR - 90 Mins - No Irr
NTR - 90 Mins - 5 Mins Irr
51
Figure 3.9. Fluorescence emission of SOS-G (1 μM) in a sample of 5 μM p-NBMB, 0.1 mM NADH in 50%
PBS/D2O mixture with 1% DMSO after 90 minutes incubation with 0.28 µM NTR, without irradiation (red
curve) and with 5 minutes irradiation (blue curve) at 625 nm (2.6 mW).
To validate the results of the SOS-G assay, a second fluorescence assay based upon the reactive
oxygen species (ROS) sensor, 2′,7′-Dichlorodihydrofluorescein diacetate (DCFH-DA) was
performed65. As shown in Figure 3.10, DCFH-DA is a reduced dichlorofluorescein chromophore
with acetate protected xanthene hydroxyls to endow cell permeability65. For the desired in vitro
assay, the acetate groups must first be cleaved using a solution of 0.01 N sodium hydroxide
(NaOH), to liberate the active reduced non-fluorescent ROS sensor, DCFH (Reduced
dichlorofluorescein) (Figure 3.10)65. If ROS species are produced by the molecule of interest, the
reduced non-fluorescent chromophore (DCFH) is then oxidized to its fluorescent analogue, DCF
(Figure 3.10)65. If singlet oxygen generation by p-NBMB is NTR activatable, an increase in
fluorescence emission from DCFH (λem – 522 nm) should only be observed upon irradiation of the
p-NBMB sample post incubation with NTR. As demonstrated in Figure 3.11, irradiation of the
DCFH sample with only p-NBMB produced a 3.2-fold increase in fluorescence. This background
increase in fluorescence was attributed to spontaneous oxidation of DCFH to DCF by the
environment. On the other hand, irradiation post 1.5-hour incubation of the sample with NTR was
found to induce a 6.5-fold increase in fluorescence (Figure 3.12). This fluorescence increase
52
indicated the successful generation of singlet oxygen species (a type of ROS), consistent with the
SOS-G assay. Therefore, it was concluded that p-NBMB exhibits NTR activatable behavior.
Figure 3.10. A schematic of the mechanism of activation of the ROS sensor, DCFH-DA. For in vitro testing, the
diacetate groups must first be cleaved from the scaffold to liberate the active non-fluorescent sensor, DCFH. In
the presence of ROS species, DCFH is oxidized to its fluorescent analogue DCF. This Figure was obtained from
[65].
Figure 3.11. Fluorescence emission of DCFH (1 μM) in a sample of 5 μM p-NBMB, 0.1 mM NADH in 50%
PBS/D2O mixture with 1% DMSO, without irradiation (brown curve) and with 5 minutes irradiation (green
curve) at 625 nm (2.6 mW).
550 600 6500
20
40
60
80
ROS Assay
Wavelength
Flu
ore
sen
ce I
nte
nsi
ty
DCFH - No Irr
DCFH - 5 Mins Irr
53
Figure 3.12. Fluorescence emission of DCFH (1 μM) in a sample of 5 μM p-NBMB, 0.1 mM NADH in 50%
PBS/D2O mixture with 1% DMSO after 90 minutes incubation with 0.28 µM NTR, without irradiation (red
curve) and with 5 minutes irradiation (blue curve) at 625 nm (2.6 mW).
Future directions & experiments
As demonstrated in the in vitro analysis above, p-NBMB is an NTR activatable MB probe with
enzyme triggered singlet oxygen production. Although this is a promising foundation, it should be
noted that the in vitro analysis is performed with an oxygen insensitive, type I NTR. Therefore,
further in cellulo analysis needs to be performed to validate the utility of p-NBMB as a PDT probe
in a hypoxic setting.
To begin, the cellular permeability and dark toxicity of p-NBMB and the parent MB dye should
be investigated in several different cell lines known to overexpress NTR under hypoxia such as
A549 and MCF-7. Once the dark toxicity threshold has been determined, the appropriate
concentrations of p-NBMB should be incubated with cells under normoxia and various extents of
hypoxia with subsequent irradiation to measure difference in phototoxicity. Since the employed
cell lines overexpress NTR under hypoxia, p-NBMB should only be phototoxic under such
conditions. If such results are obtained, the efficacy of p-NBMB should be further examined in a
mouse models.
550 600 6500
200
400
600
800
1000
ROS Assay
Wavelength
Flu
ore
sen
ce I
nte
nsi
ty
DCFH - NTR - No Irr
DCFH - NTR - 5 Mins Irr
54
Materials & methods
General Methods
All reactions were conducted in oven-dried glassware under atmospheric conditions, without the
use of inert gas protection. All reagents for which the synthesis is not provided were purchased
from Sigma Aldrich or Alfa Aesar and used as purchased without further purification. Final probe
solutions were prepared using high grade DMSO from Thermo Fisher Scientific. PBS pH 7.4 (1X)
buffer was purchased from Thermo Fisher Scientific. Fluorescent spectra were obtained using a
Shimadzu RF-6000 Spectro fluorophotometer, while UV-Visible spectra were obtained using a
Shimadzu UV-1800. Irradiation of the sample was conducted using the 625 nm mounted LED by
Thorlabs. The concentration of p-NBMB was estimated using the extinction coefficient of
methylene blue at 665 nm (91000 M-1cm-1) as reported in literature13.
UV-Visible NTR Activatability Assay
Using a 60 𝜇L quartz cuvette, the UV-Vis spectrophotometer was blanked with PBS pH 7.4. Then,
0.6 μL of a 172 μM p-NBMB stock solution (in DMSO) and 6 μL of a 1 mM NADH stock solution
(in DDI H2O) were added to 52.8 μL PBS buffer to obtain a UV-Vis spectrum of p-NBMB (final
concentration 1.72 μM). After 5 minutes of incubation a second UV-Vis spectrum was obtained
to ensure no change due to stability of the caged probe. Then, 0.6 μL of a 28 μM NTR stock
solution (final concentration 280 nM) was added and UV-Vis spectra were collected every 5
minutes until no further change in the spectrum was observed (60 minutes).
For the kinetic experiment, the procedure was repeated as mentioned above but by monitoring the
change at 667 nm as a function of time. The rates of change were calculated by measuring the
initial rates.
Singlet-Oxygen Production
Without NTR: 0.6 𝜇L of SOS-G (100 𝜇M in methanol) (final concentration 1 𝜇M), 0.6 μL of a
500 μM p-NBMB stock solution (in DMSO) and 6 μL of a 1mM NADH stock solution (in DDI
H2O) were added to a 60 𝜇L quartz cuvette containing 30 𝜇L D2O and 22.8 𝜇L pH 7.4 PBS buffer
at 37oC. A fluorescent spectrum was obtained (λ𝑒𝑥 = 495 nm, λ𝑒𝑚 = 510 to 650 nm) (3nm
excitation and emission slit width). The sample was irradiated at 625 nm (2.6 mW) for 5 minutes.
55
Another fluorescent spectrum was obtained to measure any changes due to irradiation of the
sample in the absence of NTR.
With NTR: 0.6 𝜇L of SOS-G (100 𝜇M in methanol) (final concentration 1 𝜇M), 0.6 μL of a 500
μM p-NBMB stock solution (in DMSO), 6 μL of a 1 mM NADH stock solution (in DDI H2O) and
0.6 μL of a 28 μM NTR stock solution (final concentration 280 nM) were added to a 60 𝜇L quartz
cuvette containing 30 𝜇L D2O and 22.2 𝜇L pH 7.4 PBS buffer. The mixture was incubated at 37oC
for 90 minutes. A fluorescent spectrum was obtained (λ𝑒𝑥 = 495 nm, λ𝑒𝑚 = 510 to 650 nm) (3nm
excitation and emission slit width). The sample was then irradiated at 625 nm (2.6 mW) for 5
minutes and a second fluorescent spectrum was obtained to measure any changes due to irradiation
of the sample in the presence of NTR.
ROS production
Without NTR: A 20 𝜇M stock solution of the active ROS sensor (DCFH-DH) was prepared by
diluting a 100 𝜇M stock solution of the diacetate derivative of the ROS sensor in 0.01 N sodium
hydroxide. Next, 3 𝜇L of the active ROS sensor solution, 0.6 μL of a 500 μM p-NBMB stock
solution (in DMSO) and 6 μL of a 1 mM NADH stock solution (in DDI H2O) were added to a 60
𝜇L quartz cuvette containing 20.4 𝜇L pH 7.4 PBS buffer and 30 𝜇L D2O at 37oC. A fluorescent
spectrum was obtained (λ𝑒𝑥 = 495 nm, λ𝑒𝑚 = 510 to 650 nm) (3nm excitation and emission slit
width). The sample was irradiated at 625 nm (2.6 mW) for 5 minutes. Another fluorescent
spectrum was obtained to measure any changes due to irradiation of the sample in the absence of
NTR.
With NTR: A 20 𝜇M stock solution of the active ROS sensor (DCFH-DH) was prepared by
diluting a 100 𝜇M stock solution of the diacetate derivative of the ROS sensor in 0.01 N sodium
hydroxide. Next, 3 𝜇L of the active ROS sensor solution, 0.6 μL of a 500 μM p-NBMB stock
solution (in DMSO), 6 μL of a 1 mM NADH stock solution (in DDI H2O) and 0.6 μL of a 28 μM
NTR stock solution (final concentration 280 nM) were added to a 60 𝜇L quartz cuvette containing
19.8 𝜇L pH 7.4 PBS buffer and 30 𝜇L D2O. The mixture was incubated at 37oC for 90 minutes. A
fluorescent spectrum was obtained (λ𝑒𝑥 = 495 nm, λ𝑒𝑚 = 510 to 650 nm) (3nm excitation and
emission slit width). The sample was irradiated at 625 nm (2.6 mW) for 5 minutes. Another
56
fluorescent spectrum was obtained to measure any changes due to irradiation of the sample in the
presence of NTR
Synthesis (Refer to Figure 3.3 for full scheme)
p-NBMB (1): p-NBMB was prepared according to literature34. Under argon, 319 mg (1.00 mmol)
of Methylene blue (MB) was added to 10 mL of deionized water and 40 mL of toluene. Then, 294
mg (3.50 mmol) of sodium bicarbonate and 496 mg (2.85 mmol) of sodium dithionite were added
to the mixture and stirred at 60oC for 30 minutes behind a bomb shield. After the 30 minutes, the
leuco MB containing toluene phase was slowly transferred to a new vessel with 215 mg (1.00
mmol) of 4-Nitrobenzyl chloroformate dissolved in 40 mL toluene, maintained in an ice bath. The
mixture was allowed to stir overnight. The organic solution was then washed 5X with 30 mL
deionized water and dried with sodium sulphate. The toluene was then removed in vacuo and the
product was precipitated with cold methanol to obtain p-NBMB as orange crystals (2.5 mg (0.005
mmol), yield 0.5%). MS (ESI+) calculated for [M+H]+: 465.54 Da, Found 465.30 Da. See
appendix A for the spectra.
57
Chapter 4 3AIC: A Novel Coumarin Based Photosensitizer
Why does the world need a coumarin photosensitizer (PS)?
The term photodynamic was first used in 1903 by Herman Von
Tappeiner and A. Jesionek, who topically applied eosin (Figure 4.1)
in combination with white light to combat skin cancer18. Since then,
the field of photodynamic therapy (PDT) has emerged into an
extremely powerful tool to combat cancer, with several
photosensitizer drugs (PSs) gaining clinical approval in various
countries13,18,20. Unfortunately, as highlighted in the previous
chapter, the clinical utility of PDT for cancer remains limited. One
of the key hinderances in widespread adoption of PDT is the absence of structural features on
clinically approved PSs, which allow for differentiation between healthy and cancer cells13. As a
result, current clinically approved PSs induce phototoxicity in healthy cells adjacent to the cancer
cells during irradiation. In addition, the tetrapyrrole family of PSs, which makes up most clinically
approved PSs, suffer from poor water solubility and poor clearance leading to prolonged skin
sensitivity19,20,24. Furthermore, although commercially available, many porphyrins with PDT
properties (such as Pyropheophorbide-a) are extremely expensive and synthetically challenging to
prepare. On the other hand, non-tetrapyrrole based PSs such as methylene blue and Rose Bengal
suffer from excessive dark toxicity and poor photostability, respectively19,25. These limitations of
pre-existing PSs act to bottleneck the development of targeting strategies via structural
improvements, which may endow these molecules with greater selectivity for cancer cells over
healthy cells and thereby reduce toxicity. As such, the development of novel PSs with good
photostability and water solubility, that can be prepared in a facile manner with minimal
purification are highly warranted. Such PSs would allow for the development of targeting
strategies on a proof of principle basis, which may then be further extrapolated to other pre-existing
PSs. In this chapter, the facile development and subsequent photophysical characterization of a
novel PS based upon an iodinated 3-aminocoumarin scaffold is discussed. The coumarin
chromophore is ideal for the development of a PS, as the scaffold is known to be bioactive with an
abundance of literature on synthesis. In fact, one of oldest family of PSs, psoralens, is based upon
a furanocoumarin structure (Figure 4.2)66. Although, the psoralens are capable of singlet oxygen
Figure 4.1. Chemical Structure
of Eosin.
58
production, their quantum yield of singlet oxygen is low (between
0.2-0.4)66. This limitation has indorsed the development of other
coumarin based PSs which have greater singlet oxygen quantum
yields66–68. Unfortunately, all these PSs require lengthy synthesis
with purification at each step. In addition, these coumarin based PSs
lack any functional handles (such as amine or carboxylic acid) which may be further exploited to
introduce targeting moieties for better selectivity. To improve upon such limitations, the
development of a novel coumarin based PS, 3-amino-6,8-diiodocoumarin (“3AIC”) was proposed.
Built upon a simple 3-aminocoumarin (3AC) structure, 3AIC features iodine atoms at the 6 and 8
positions of the scaffold, promoting intersystem crossing and therefore inducing singlet oxygen
production. In addition, the inclusion of an amine handle allows for future structural modifications
of the PS with targeting moieties to aid in the development of cancer targeted PSs.
Results and discussion
To begin, 3AIC was synthesized utilizing a combination of literature based upon the synthesis of
3AC (Figure 4.3)69–71. To minimize purification steps, synthetic protocols utilizing simple product
precipitation were found69–71. Then, to introduce iodine atoms at the desired 6 and 8 positions, the
synthetic pathway was modified to include the commercially available and inexpensive 3,5-
diiodosalicyladehyde instead of the non-iodinated analogue, salicylaldehyde. It is worth noting,
the synthetic pathway can be further shortened to two easy steps, if N-acetylglycine ($13.80
CAD)72 is simply purchased. For details on the synthesis, refer to the materials and methods section
below.
Once synthesized, a UV-Visible spectrum of 3AIC was obtained and compared to that of the
commercially available non-iodinated variant, 3AC. As shown in Figure 4.4, 3AIC was found to
have a similar shape to 3AC but the inclusion of the iodines appeared to induce a slight
bathochromic shift. Note, the samples of 3AC and 3AIC were prepared to have the same
absorbance at 365 nm (Figure 4.4), which will be the wavelength used for photoexcitation in
subsequent singlet oxygen and ROS generation assays.
Figure 4.2. Chemical Structure
of Psoralen.
59
Figure 4.3. Synthetic scheme for the synthesis of 3AIC and associated intermediates.
Figure 4.4. The UV-Visible spectrum of 3-aminocoumarin (3AC) in the blue curve and 3-amino-6,8-diiodocoumarin (3AIC)
in the black curve in PBS with 1% DMSO. Note, the concentrations of both samples 3AC (109 μM) and 3AIC (8.25 μM)
were used such that the both compounds had the same absorbance at 365 nm (the wavelength used for photoexcitation).
To measure the singlet oxygen production, a fluorescence assay based upon the singlet oxygen
sensor green (SOS-G) was performed64,73. For details on the SOS-G assay refer to chapter 3. In the
case of singlet oxygen generation by 3AIC, if SOS-G and 3AIC are incubated together and the
sample is irradiated with a 365 nm LED, then if singlet oxygen is produced, one should observe
an increase in fluorescence at the emission wavelength of fluorescein (λ𝑒𝑚 = 525 nm). As shown
in Figure 4.5A, irradiation of SOS-G (1 μM) at 365 nm for 5 minutes, did not induce an increase
in fluorescence emission at 525 nm. However, when 3AIC (8.25 μM) was present in the solution
60
mixture, irradiation for 5 minutes at 365 nm, resulted in an increase in fluorescent emission at 525
nm, as would be expected if singlet oxygen was produced (Figure 4.5B).
A
B
To confirm the facilitation of intersystem crossing by the presence of iodine atoms, a further SOS-
G singlet oxygen assay was performed with the non-iodinated 3AC scaffold. As shown in Figure
4.6, no increase in fluorescence from SOS-G (1 μM) was observed upon irradiation either in the
absence (Figure 4.6A) or presence (Figure 4.6B) of the 3AC (109 μM), indicating that the non-
iodinated scaffold cannot produce singlet oxygen. In other words, the intersystem crossing
promoted by the iodines at the 6 and 8 positions of 3AIC is imperative in its ability to act as a PS.
Figure 4.5. A) Fluorescence emission of SOS-G (1 μM) in the absence of 3AIC, without irradiation (red curve) and with
irradiation (1.1 mW) (blue curve) at 365 nm in 50% PBS/D2O mixture with 1% DMSO. B) Fluorescence emission of SOS-
G (1 μM) in the presence of 3AIC (8.25 μM), without irradiation (red curve) and with irradiation (1.1 mW) (blue curve) at
365 nm in 50% PBS/D2O mixture with 1% DMSO. Refer to the materials and methods section for details.
61
A
B
Next, the results of the SOS-G singlet oxygen assay were further validated via investigation of the
reactive oxygen species (ROS) production by 3AIC using a general ROS sensor, 2′,7′-
Dichlorodihydrofluorescein diacetate (DCFH-DA)65. For details on the DCFH-DA ROS assay,
refer to chapter 3. If ROS species are produced by 3AIC, one should observe an increase in
fluorescent emission at 522 nm. As shown in Figure 4.7B, 5-minute irradiation of a sample
containing both DCFH (1 μM) and 3AIC (8.25 μM), resulted in an approximately 43-fold increase
in fluorescence at 522 nm, relative to the emission of a sample without irradiation. The ROS assay
supported the data observed in the SOS-G assay, that is, 3AIC is a proficient PS capable of
producing singlet oxygen and potentially other ROS species as well. It is worth noting, that the
Figure 4.6. A) Fluorescence emission of SOS-G (1 μM) in the absence of 3AC, without irradiation (red curve) and with
irradiation (1.1 mW) (green curve) at 365 nm in 50% PBS/D2O mixture with 1% DMSO. B) Fluorescence emission of SOS-
G (1 μM) in the presence of 3AC (109 μM), without irradiation (brown curve) and with irradiation (1.1 mW) (blue curve)
at 365 nm in 50% PBS/D2O mixture with 1% DMSO. Refer to the materials and methods section for details.
62
oxidation required for the activation of DCFH, can occur simply due to spontaneous oxidation by
the atmospheric environment leading to a small background increase in fluorescence (about 3 to
4-fold) as shown in Figure 4.7A. The assay was repeated with the non-iodinated variant 3AC
(Figure 4.8), to confirm that the iodines are responsible for the PS properties of 3AIC. As shown
in Figure 4.8, the increase (~3 fold) observed in the fluorescence emission upon irradiation of the
sample containing 3AC (109 μM) and DCFH (1 μM), matched that of the background increase
upon the irradiation of DCFH (1 μM) in the absence of 3AC, indicating that 3AC cannot generate
ROS species. Therefore, consistent with the SOS-G data, 3AC does not have any PS properties.
A
B
550 600 650
-50
0
50
100
150
200
250
ROS Assay
Wavelength (nm)
Flu
ore
sen
ce I
nte
nsi
ty
No 3-AIC No Irr
No 3-AIC 5 Mins Irr
550 600 6500
2000
4000
6000
ROS Assay
Wavelength (nm)Flu
orese
nce I
nte
nsi
ty
3-AIC No Irr
3-AIC 5Mins Irr
Figure 4.7. A) Fluorescence emission of DCFH (1 μM) in the absence of 3AIC, without irradiation (blue curve) and with
irradiation (1.1 mW) (red curve) at 365 nm in 50% PBS/D2O mixture with 1% DMSO. Note, the background increase (3-
4 fold) appears to be due to spontaneous oxidation of the sensor by the atmospheric oxygen. B) Fluorescence emission of
DCFH (1 μM) in the presence of 3AIC (8.25 μM), without irradiation (blue curve) and with irradiation (1.1 mW) (red
curve) at 365 nm in 50% PBS/D2O mixture with 1% DMSO. Refer to the materials and methods section for details.
63
A
B
Since some iodinated PSs such as Rose Bengal are known to undergo photoinduced deiodination,
resulting in loss of PS properties25, the photostability of the 3AIC was investigated. As shown in
Figure 4.9, 3AIC (20 𝜇𝑀) was shown to undergo minimal change in absorbance upon intense
irradiation at 365 nm (1.1 mW) for up to 30 minutes. Thus, 3AIC is a photostable PS. In addition,
because these assays were performed in PBS buffer, it is clear 3AIC also exhibits water solubility.
550 600 6500
50
100
150
ROS Assay
Wavelength (nm)F
luorese
nce I
nte
nsi
ty No 3AC No Irr
No 3AC 5 Mins Irr
550 600 6500
100
200
300
400
ROS Assay
Wavelength (nm)
Flu
orese
nce I
nte
nsi
ty 3AC No Irr
3AC 5 Mins Irr
Figure 4.8. A) Fluorescence emission of DCFH (1 μM) in the absence of 3AC, without irradiation (blue curve) and with
irradiation (1.1 mW) (red curve) at 365 nm in 50% PBS/D2O mixture with 1% DMSO. Note, the background increase (3-4
fold) appears to be due to spontaneous oxidation of the sensor by the atmospheric oxygen. B) Fluorescence emission of
DCFH (1 μM) in the presence of 3AC (109 μM), without irradiation (blue curve) and with irradiation (1.1 mW) (red curve)
at 365 nm in 50% PBS/D2O mixture with 1% DMSO. Refer to the materials and methods section for details.
64
Future directions & experiments
Although the photostability and in vitro competence of 3AIC as a PS have been demonstrated, a
few more important experiments are yet to be conducted. To begin, concentrations of the 3AIC
have been estimated using the literature extinction coefficient value of the non-iodinated variant
3AC at 324 nm (13803 M-1cm-1) in methanol74. While structurally similar, the two compounds are
not identical, and hence the extinction coefficient of 3AIC should be experimentally determined
to ensure that the concentrations utilized in the above-mentioned experiments are accurately
described. Another in vitro experiment that remains to be completed, is the determination of the
quantum yield of singlet oxygen (Φ∆) of 3AIC and how that compares to other PSs. It is expected
that the efficient intersystem crossing brought on by the presence of the iodine atoms coupled with
the rigid structure will grant 3AIC a superior Φ∆ value in comparison to the psoralens which rely
solely on structural rigidity66.
Once these in vitro experiments have been conducted, the next task is to apply 3AIC to multiple
cancer cell lines and investigate the cell permeability, dark toxicity, and phototoxicity. To detect
Figure 4.9. 20 μM 3AIC in PBS (1% DMSO) irradiated at 365 nm (1.1 mW) for various time points.
65
the in cellulo singlet oxygen production, 3AIC must be applied in combination with DCFH-DA,
which upon singlet oxygen production will emit green fluorescence. If the cellular efficacy of
3AIC is deemed satisfactory, further structural modifications should be performed to introduce
cancer targeting moieties to endow greater selectivity for cancer cells vs. healthy cells.
Materials & methods
General Methods
All reactions were conducted in oven-dried glassware under atmospheric conditions, without the
use of inert gas protection. All reagents for which the synthesis is not provided were purchased
from Sigma Aldrich or Alfa Aesar and used as purchased without further purification. NMR
solvents were purchased from Cambridge isotope laboratories and used without further
purification. Final probe solutions were prepared using high grade DMSO from Thermo Fisher
Scientific. PBS pH 7.4 (1X) buffer was purchased from Thermo Fisher Scientific. NMR data was
collected using a Bruker Avance III 400 MHz spectrometer, with chemical shifts reported in ppm
relative to the residual solvent resonance peaks. Fluorescent spectra were obtained using a
Shimadzu RF-6000 Spectro fluorophotometer while UV-Vis spectra were obtained using a
Shimadzu UV-1800. Irradiation of the sample was conducted using 365 nm Mounted LED by
Thorlabs. The concentrations of 3AIC and 3AC stock samples were estimated using the extinction
coefficient of 3-aminocoumarin at 324 nm (13803 M-1cm-1) in methanol as reported in literature74.
UV-Vis Spectroscopy
Using a 60 𝜇L quartz cuvette, the UV-Vis spectrophotometer was blanked with pH 7.4 PBS. Then,
0.6 𝜇L of a 0.825 mM 3AIC stock solution (in DMSO) was added to 59.4 𝜇L PBS buffer to obtain
a UV-Vis spectrum of 3AIC (final concentration 8.25 𝜇M). The procedure was then repeated with
a stock solution of 3AC.
Singlet-Oxygen production
0.6 𝜇L of SOS-G (100 𝜇M in methanol) (final concentration 1 𝜇M) was added to a 60 𝜇L quartz
cuvette containing 30 𝜇L D2O and 29.1 𝜇L PBS pH 7.4 buffer. A fluorescent spectrum was
obtained (λ𝑒𝑥 = 495 nm, λ𝑒𝑚 = 510 to 650 nm) (3nm excitation and emission slit width). As a
control, the sample was irradiated at 365 nm (1.1 mW) for 5 minutes. Another fluorescent spectrum
66
was obtained to measure any changes due to irradiation of the singlet oxygen sensor. Next, 0.3 𝜇L
of 3AIC (0.825 mM in DMSO) (final concentration 4.13 𝜇M) was added to the cuvette. A
fluorescent spectrum was obtained after which, the sample was irradiated at 365 nm (1.1 mW) for
5 minutes. A final spectrum was obtained to investigate any changes due to the production of
singlet oxygen by 3AIC. The procedure was repeated for 3AC.
ROS production
A 20 𝜇M stock solution of the active ROS sensor (DCFH-DH) was prepared by diluting a 100 𝜇M
stock solution of the diacetate derivative of the ROS sensor in 0.01 N sodium hydroxide. Next, 3
𝜇L of the active ROS sensor solution was added to a 60 𝜇L quartz cuvette containing 25 𝜇L PBS
buffer pH 7.4 and 30 𝜇L D2O. A fluorescent spectrum of the sensor was obtained (λ𝑒𝑥 = 495 nm,
λ𝑒𝑚 = 510 to 650 nm) (3nm excitation and emission slit width). The sample was then irradiated at
365 nm (1.1 mW) for 5 minutes and another fluorescent spectrum was measured. Next, 2 𝜇L of a
3AIC stock solution (150 𝜇M in DMSO) (final concentration 5 𝜇M) was added to the cuvette and
the sample was irradiated at 365 nm (1.1 mW) for 5 minutes. A final fluorescent spectrum was
obtained to investigate any changes due to ROS production by 3AIC. The procedure was repeated
for 3AC.
Photostability
A 20 𝜇𝑀 solution of 3AIC in PBS (1% DMSO) was prepared in a 60 𝜇𝐿 quartz cuvette. The
sample was irradiated at 365 nm (1.1 mW) at 5-minute time intervals for up to 30 minutes and the
UV-Vis spectrum was obtained at each time point. The procedure was repeated 3 times and the
average absorbance values at 365 nm were plotted as a function of time.
Synthesis (Refer to Figure 4.3 for full scheme)
N-Acetylglycine (1): N-acetylglycine was synthesized according to literature69. 2.2 grams (29
mmol) of glycine in 10 mL of DI water were added to a round bottom flask. The mixture was
67
stirred at room temperature until the glycine was fully dissolved. Then, 5 mL (52 mmol) of acetic
anhydride was added to the mixture. The mixture was further stirred at room temperature for 30
minutes resulting in the round bottom becoming hot and the N-acetylglycine precipitating out. The
round bottom was then placed in the fridge (4 oC) overnight to complete precipitation. The
precipitate was isolated via vacuum filtration and washed with cold water to obtain the desired
product as a white solid (1.19 g (10.2 mmol), yield 35%). 1HNMR (400 MHz DMSO-d6): 1.84 (s,
3H), 3.72 (d, 2H, J = 6Hz), 8.16 (s, 1H), 12.48 (s, 1H). See Appendix 1 for spectra.
3AIC-Acetate (2): 3AIC-acetate was synthesized according to literature70, except 3,5-
diiodosalicyladehyde was used instead of salicylaldehyde. 870 mg (10.6 mmol) of sodium acetate
was added to a round bottom flask with 1.5 mL (15.9 mmol) acetic anhydride. The mixture was
stirred until the sodium acetate was fully dissolved. Then, 307 mg (2.62 mmol) N-Acetylglycine
was added to the round bottom followed by addition of 1 g (2.67 mmol) of 3,5-
diiodosalicyladehyde. The mixture was refluxed at 120oC for 3 hours. During this time, the
solution slowly turned brown and viscous. The mixture was allowed to cool to room temperature
to obtain a brown solid. Cold water was added to the precipitate and a spatula was used to break
up the solid. The slurry was then vacuum filtered and washed with cold water (2X). The precipitate
was then further washed with cold ethyl acetate to obtain the desired compound as an off white
solid (212 mg (0.466 mmol), yield 17.8%). 1HNMR (400 MHz DMSO-d6): 2.17 (s, 3H), 8.11 (d,
1H, J = 2.02 Hz), 8.19 (d, 1H, J = 2.02 Hz), 8.49 (s, 1H), 9.89 (s, 1H). See Appendix 1 for spectra.
3AIC (3): The synthesis of 3AIC was adapted from literature71. Briefly, an oil bath was preheated
to 120oC and 10 mL of a 70% H2SO4 solution (prepared by adding 5.8 mL of concentrated H2SO4
to 4.2 mL of DI water on ice) was added. Next, 35 mg (0.08 mmol) of 3AIC-acetate (compound
68
2) was added. The cloudy mixture was refluxed with continuous stirring until the solution turned
clear yellow (after approximately 1.5 hours). The solution was then allowed to come to room
temperature and 20.0 mL of ice cold water was added resulting in the precipitation of a white solid.
Next, about 25.0 mL of a cold 2N sodium hydroxide solution was added to the round bottom
resulting in further precipitation of a white solid. The precipitate was vacuum filtered, washed with
cold DI water and then dried under vacuum with gentle heating with a heat gun. The desired
product was isolated as an off white solid (22.0 mg (0.053 mmol), yield 69%). 1HNMR (400 MHz
CDCl3): 4.42 (s, 2H), 6.46 (s, 1H), 7.57 (s, 1H), 7.98 (s, 1H). See Appendix 1 for spectra.
69
Concluding Remarks
Photodynamic therapy (PDT) is a clinically approved cancer treatment which relies upon the
combined action of a photosensitizer drug (PS), light, and oxygen, to generate cytotoxic reactive
oxygen species to kill cells. The approach provides is an alternative to traditional cancer treatments
such as surgery and chemotherapy. Unfortunately, the clinical utility of this treatment remains
limited, partially due to the unselective nature of the PS drugs which cannot distinguish between
cancer and healthy cells, and thereby induce phototoxicity in healthy cells alongside cancer cells.
Improvement in the selective behavior of PSs is therefore imperative in increasing the clinical
utility of PDT. Pro-drug variants of pre-existing PSs that are activated by enzymes overexpressed
in cancer cells offer a potent solution. In this regard, the development and examination of two such
activatable PSs, Probe 1 and p-NBMB (Figure 5.1), targeted by the cancer biomarkers, O6-
methylguanine DNA methyltransferase (MGMT) and Nitroreductase (NTR), respectively, were
discussed in this body of work.
MGMT is a DNA repair enzyme that repairs alkylations at the O6-position of guanine by
transferring the alkyl group to a cysteine residue at its active site37,38. Several pseudosubstrates
have been developed which mimic alkylated guanine and thereby inhibit the enzyme. For
developing an MGMT activatable PS probe, one such inhibitor, O6-benzylguanine (O6-BG), was
modified with a commercially available PS, Rose Bengal, and the appropriate FRET quencher,
Figure 5.1. Structure of the examined enzyme activatable PS probes.
70
black hole quencher 2 (BHQ2), to generate a FRET quenched PS probe. The transfer of the PS
containing benzyl group at the O6 position of guanine to the enzyme active site should separate the
PS from the quencher, and thereby activate the PS. Unfortunately, such transfer was not observed.
To identify the source of this failure, the probe was dissected such that the quencher portion was
eliminated. In addition, the PS was switched from Rose Bengal to Pyropheophorbide-a due to
photostability issues associated with Rose Bengal25. The resultant always on probe, P1NQ (Figure
5.2), was found to successfully transfer the PS onto MGMT, albeit with poor efficiency (see
chapter 2). Nonetheless, P1NQ serves as a good starting point for the subsequent development of
functional and efficient FRET-based MGMT activatable PS probes. That being said, there are
some considerations with the FRET-based approach. The final probe with both the PS and the
quencher is going to be bulky and hydrophobic and as such, there may be issues in solubility and
cellular permeability. If the probe has too great of a hydrophobic character, it may be trapped
within the membrane and as such, would not be activated due to the lack of appropriate cellular
localization. Fortunately, such issues may be mitigated by introducing peg-based linkers between
the O6-BG and the PS and quencher to endow greater hydrophilic character. Alternatively, the PeT
quenching abilities of guanine may be also utilized with the appropriate PS dyes to develop a PeT-
based MGMT activatable PS probe, which does not require an accessary quencher and therefore
abolishes the introduction of excessive bulk and hydrophobicity.
Figure 5.2. The chemical structure of probe 1 no quencher (P1NQ).
The second target cancer biomarker, often overexpressed in hypoxia, exploited for activation of a
PS probe was NTR. It is responsible for the conversion of nitro groups (especially nitroarenes) to
their amine counterparts with the assistance of the 2-electron donor molecule, NADH59. Based
upon the action of the enzyme, a photoinactive derivative of methylene blue, called p-NBMB, with
a NTR specific 4-nitrobenzyl carbamate cage, was developed by the Jo group34. The probe was
used as a fluorescent sensor for NTR in anaerobic bacteria with no applications in the realm of
71
PDT34. Consequently, the probe was synthesized and subsequently investigated for its ability to
act as a NTR activatable PS probe. In vitro analysis of p-NBMB with NTR showed that the probe
can generate singlet oxygen only upon action of NTR (see chapter 3). However, in cellulo
evaluation of p-NBMB under various extents of hypoxia should be conducted to measure the
activatability and selectivity of the probe. In addition, the concentration of p-NBMB employed in
the assay needs to be carefully considered to minimize the dark toxicity from the methylene blue
and the eliminated caged by-product.
In the process of developing activatable PS probes, it was realized that
existing PSs have many other drawbacks in addition to the indiscriminate
phototoxicity. For example, Rose Bengal exhibits photoinduced
deiodination which results in a loss of PS properties25, while porphyrin-based
PSs are difficult to synthesize and exhibit poor water solubility. To this end,
a novel 3-aminocoumarin based PS, called 3AIC (Figure 5.3), was
developed via introduction of iodines at the 6 and 8 positions. In vitro analysis of 3AIC showed
that it can produce singlet oxygen species, while the non-iodinated analogue, 3AC, cannot. The
PS was found to exhibit good photostability, water solubility and could be prepared from
inexpensive commercially available precursors in 2 easy steps with minimal purification. Given
these promising findings, the singlet oxygen quantum yield and the extinction coefficient of 3AIC
should be measured along with the cellular efficacy. In addition, the wavelength of photoexcitation
should ideally be improved via extension of the conjugation in the system such that it absorbs
within the biological optical window.
Figure 5.3. Structure
of the 3AIC.
72
References
(1) Nagai, H.; Kim, Y. H. Cancer Prevention from the Perspective of Global Cancer Burden
Patterns. Journal of Thoracic Disease 2017, 9 (3), 448–451.
(2) Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global Cancer
Statistics. CA: A Cancer Journal for Clinicians 2011, 61 (2), 69–90.
(3) Hanahan, D.; Weinberg, R. A. The Hallmarks of Cancer. Cell 2000, 100 (1), 57–70.
(4) Canadian Cancer Statistics 2018. Canadian Cancer Society 2018.
(5) Carter, S. K.; Slavik, M. Chemotherapy of Cancer. Annu. Rev. Pharmacol. 1974, 14 (1),
157–183.
(6) Ades, F.; Tryfonidis, K.; Zardavas, D. The Past and Future of Breast Cancer Treatment—
from the Papyrus to Individualised Treatment Approaches. ecancermedicalscience 2017,
11, 746.
(7) Cady B. Basic Principles in Surgical Oncology. Archives of Surgery 1997, 132 (4), 338–
346.
(8) Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug Resistance in Cancer: Role of ATP–
Dependent Transporters. Nature Reviews Cancer 2002, 2, 48.
(9) Brown, S.; Kirkbride, P.; Marshall, E. Radiotherapy in the Acute Medical Setting. Clinical
Medicine 2015, 15 (4), 382–387.
(10) Luqmani, Y. A. Mechanisms of Drug Resistance in Cancer Chemotherapy. Medical
Principles and Practice 2005, 14(suppl 1) (Suppl. 1), 35–48.
(11) Oun, R.; Moussa, Y. E.; Wheate, N. J. The Side Effects of Platinum-Based Chemotherapy
Drugs: A Review for Chemists. Dalton Trans. 2018, 47 (19), 6645–6653.
(12) Nurgali, K.; Jagoe, R. T.; Abalo, R. Editorial: Adverse Effects of Cancer Chemotherapy:
Anything New to Improve Tolerance and Reduce Sequelae? Frontiers in Pharmacology
2018, 9, 245.
(13) Lovell, J. F.; Liu, T. W. B.; Chen, J.; Zheng, G. Activatable Photosensitizers for Imaging
and Therapy. Chem. Rev. 2010, 110 (5), 2839–2857.
(14) Yoo, J.-O.; Ha, K.-S. Chapter Four - New Insights into the Mechanisms for Photodynamic
Therapy-Induced Cancer Cell Death. In International Review of Cell and Molecular
Biology; Jeon, K. W., Ed.; Academic Press, 2012; Vol. 295, pp 139–174.
73
(15) Bacellar, O. I.; Tsubone, M. T.; Pavani, C.; Baptista, S. M. Photodynamic Efficiency:
From Molecular Photochemistry to Cell Death. International Journal of Molecular
Sciences 2015, 16 (9).
(16) Agostinis, P.; Berg, K.; Cengel, K. A.; Foster, T. H.; Girotti, A. W.; Gollnick, S. O.; Hahn,
S. M.; Hamblin, M. R.; Juzeniene, A.; Kessel, D.; et al. Photodynamic Therapy of Cancer:
An Update. CA: A Cancer Journal for Clinicians 2011, 61 (4), 250–281.
(17) Dobson, J.; de Queiroz, G. F.; Golding, J. P. Photodynamic Therapy and Diagnosis:
Principles and Comparative Aspects. The Veterinary Journal 2018, 233, 8–18.
(18) Dolmans, D. E. J. G. J.; Fukumura, D.; Jain, R. K. Photodynamic Therapy for Cancer.
Nature Reviews Cancer 2003, 3, 380.
(19) Oniszczuk, A.; Wojtunik-Kulesza, K. A.; Oniszczuk, T.; Kasprzak, K. The Potential of
Photodynamic Therapy (PDT)—Experimental Investigations and Clinical Use.
Biomedicine & Pharmacotherapy 2016, 83, 912–929.
(20) Ormond, B. A.; Freeman, S. H. Dye Sensitizers for Photodynamic Therapy. Materials
2013, 6 (3).
(21) Allison, R. R.; Sibata, C. H. Oncologic Photodynamic Therapy Photosensitizers: A
Clinical Review. Photodiagnosis and Photodynamic Therapy 2010, 7 (2), 61–75.
(22) Kobayashi, H.; Ogawa, M.; Alford, R.; Choyke, P. L.; Urano, Y. New Strategies for
Fluorescent Probe Design in Medical Diagnostic Imaging. Chem. Rev. 2010, 110 (5),
2620–2640.
(23) Weissleder, R. A Clearer Vision for in Vivo Imaging. Nat Biotech 2001, 19 (4), 316–317.
(24) Abrahamse, H.; Hamblin, M. R. New Photosensitizers for Photodynamic Therapy.
Biochem J 2016, 473 (4), 347.
(25) Pa̧czkowski, J.; Pa̧czkowska, B.; Neckers, D. C. Photolysis Products of Rose Bengal
Lactone Diacetate. Journal of Photochemistry and Photobiology A: Chemistry 1991, 61
(1), 131–136.
(26) Wu, W.; Shao, X.; Zhao, J.; Wu, M. Controllable Photodynamic Therapy Implemented by
Regulating Singlet Oxygen Efficiency. Advanced Science 2017, 4 (7), 1700113.
(27) Fluorescence Detection Techniques. In Introduction to Fluorescence Sensing;
Demchenko, A. P., Ed.; Springer Netherlands: Dordrecht, 2009; pp 65–118.
(28) Lovell, J. F.; Chen, J.; Jarvi, M. T.; Cao, W.-G.; Allen, A. D.; Liu, Y.; Tidwell, T. T.;
Wilson, B. C.; Zheng, G. FRET Quenching of Photosensitizer Singlet Oxygen Generation.
J. Phys. Chem. B 2009, 113 (10), 3203–3211.
74
(29) Zheng, G.; Chen, J.; Stefflova, K.; Jarvi, M.; Li, H.; Wilson, B. C. Photodynamic
Molecular Beacon as an Activatable Photosensitizer Based on Protease-Controlled Singlet
Oxygen Quenching and Activation. Proc Natl Acad Sci USA 2007, 104 (21), 8989.
(30) Mechanisms of Signal Transduction. In Introduction to Fluorescence Sensing;
Demchenko, A. P., Ed.; Springer Netherlands: Dordrecht, 2009; pp 249–297.
(31) Aigner, D.; Borisov, S. M.; Klimant, I. New Fluorescent Perylene Bisimide Indicators—a
Platform for Broadband PH Optodes. Analytical and Bioanalytical Chemistry 2011, 400
(8), 2475–2485.
(32) McDonnell, S. O.; Hall, M. J.; Allen, L. T.; Byrne, A.; Gallagher, W. M.; O’Shea, D. F.
Supramolecular Photonic Therapeutic Agents. J. Am. Chem. Soc. 2005, 127 (47), 16360–
16361.
(33) Hirakawa, K.; Nishimura, Y.; Arai, T.; Okazaki, S. Singlet Oxygen Generating Activity of
an Electron Donor Connecting Porphyrin Photosensitizer Can Be Controlled by DNA. J.
Phys. Chem. B 2013, 117 (43), 13490–13496.
(34) Bae, J.; McNamara, L. E.; Nael, M. A.; Mahdi, F.; Doerksen, R. J.; Bidwell, G. L.;
Hammer, N. I.; Jo, S. Nitroreductase-Triggered Activation of a Novel Caged Fluorescent
Probe Obtained from Methylene Blue. Chemical communications (Cambridge, England)
2015, 51 (64), 12787–12790.
(35) Li, Z.; Wang, Y.-F.; Zeng, C.; Hu, L.; Liang, X.-J. Ultrasensitive Tyrosinase-Activated
Turn-On Near-Infrared Fluorescent Probe with a Rationally Designed Urea Bond for
Selective Imaging and Photodamage to Melanoma Cells. Anal. Chem. 2018, 90 (6), 3666–
3669.
(36) Sabharwal, A.; Middleton, M. R. Exploiting the Role of O6-Methylguanine-DNA-
Methyltransferase (MGMT) in Cancer Therapy. Current Opinion in Pharmacology 2006,
6 (4), 355–363.
(37) Kaina, B.; Christmann, M.; Naumann, S.; Roos, W. P. MGMT: Key Node in the Battle
against Genotoxicity, Carcinogenicity and Apoptosis Induced by Alkylating Agents. DNA
Repair 2007, 6 (8), 1079–1099.
(38) Gerson, S. L. MGMT: Its Role in Cancer Aetiology and Cancer Therapeutics. Nature
Reviews Cancer 2004, 4, 296.
(39) Roos, W. P.; Kaina, B. DNA Damage-Induced Cell Death by Apoptosis. Trends in
Molecular Medicine 2006, 12 (9), 440–450.
(40) Daniels, D. S.; Mol, C. D.; Arvai, A. S.; Kanugula, S.; Pegg, A. E.; Tainer, J. A. Active
and Alkylated Human AGT Structures: A Novel Zinc Site, Inhibitor and Extrahelical Base
Binding. EMBO J 2000, 19 (7), 1719.
(41) Christmann, M.; Verbeek, B.; Roos, W. P.; Kaina, B. O6-Methylguanine-DNA
Methyltransferase (MGMT) in Normal Tissues and Tumors: Enzyme Activity, Promoter
75
Methylation and Immunohistochemistry. Biochimica et Biophysica Acta (BBA) - Reviews
on Cancer 2011, 1816 (2), 179–190.
(42) Moore, M. H.; Gulbis, J. M.; Dodson, E. J.; Demple, B.; Moody, P. C. Crystal Structure of
a Suicidal DNA Repair Protein: The Ada O6-Methylguanine-DNA Methyltransferase
from E. Coli. The EMBO Journal 1994, 13 (7), 1495–1501.
(43) Fan, C.-H.; Liu, W.-L.; Cao, H.; Wen, C.; Chen, L.; Jiang, G. O6-Methylguanine DNA
Methyltransferase as a Promising Target for the Treatment of Temozolomide-Resistant
Gliomas. Cell Death &Amp; Disease 2013, 4, e876.
(44) McMurry, T. B. H. MGMT Inhibitors—The Trinity College–Paterson Institute
Experience, a Chemist’s Perception. DNA Repair 2007, 6 (8), 1161–1169.
(45) Schilsky, R. L.; Dolan, M. E.; Bertucci, D.; Ewesuedo, R. B.; Vogelzang, N. J.; Mani, S.;
Wilson, L. R.; Ratain, M. J. Phase I Clinical and Pharmacological Study of
<em>O</Em>6-Benzylguanine Followed by Carmustine in Patients with Advanced
Cancer. Clin Cancer Res 2000, 6 (8), 3025.
(46) Ranson, M.; Middleton, M. R.; Bridgewater, J.; Lee, S. M.; Dawson, M.; Jowle, D.;
Halbert, G.; Waller, S.; McGrath, H.; Gumbrell, L.; et al. Lomeguatrib, a Potent Inhibitor
of O6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and
Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients
with Advanced Solid Tumors. Clin Cancer Res 2006, 12 (5), 1577.
(47) Komatsu, T.; Johnsson, K.; Okuno, H.; Bito, H.; Inoue, T.; Nagano, T.; Urano, Y. Real-
Time Measurements of Protein Dynamics Using Fluorescence Activation-Coupled Protein
Labeling Method. J. Am. Chem. Soc. 2011, 133 (17), 6745–6751.
(48) Juillerat, A.; Heinis, C.; Sielaff, I.; Barnikow, J.; Jaccard, H.; Kunz, B.; Terskikh, A.;
Johnsson, K. Engineering Substrate Specificity of O6-Alkylguanine-DNA
Alkyltransferase for Specific Protein Labeling in Living Cells. ChemBioChem 2005, 6 (7),
1263–1269.
(49) Sun, X.; Zhang, A.; Baker, B.; Sun, L.; Howard, A.; Buswell, J.; Maurel, D.; Masharina,
A.; Johnsson, K.; Noren, C. J.; et al. Development of SNAP-Tag Fluorogenic Probes for
Wash-Free Fluorescence Imaging. ChemBioChem 2011, 12 (14), 2217–2226.
(50) Reinhard, J.; Hull, W. E.; von der Lieth, C.-W.; Eichhorn, U.; Kliem, H.-C.; Kaina, B.;
Wiessler, M. Monosaccharide-Linked Inhibitors of O6-Methylguanine-DNA
Methyltransferase (MGMT): Synthesis, Molecular Modeling, and Structure−Activity
Relationships. J. Med. Chem. 2001, 44 (24), 4050–4061.
(51) Doose, S.; Neuweiler, H.; Sauer, M. Fluorescence Quenching by Photoinduced Electron
Transfer: A Reporter for Conformational Dynamics of Macromolecules. ChemPhysChem
2009, 10 (9‐10), 1389–1398.
76
(52) Heinlein, T.; Knemeyer, J.-P.; Piestert, O.; Sauer, M. Photoinduced Electron Transfer
between Fluorescent Dyes and Guanosine Residues in DNA-Hairpins. J. Phys. Chem. B
2003, 107 (31), 7957–7964.
(53) Zhang, C.-J.; Li, L.; Chen, G. Y. J.; Xu, Q.-H.; Yao, S. Q. One- and Two-Photon Live Cell
Imaging Using a Mutant SNAP-Tag Protein and Its FRET Substrate Pairs. Org. Lett.
2011, 13 (16), 4160–4163.
(54) Kolmakov, K.; Wurm, C. A.; Meineke, D. N. H.; Göttfert, F.; Boyarskiy, V. P.; Belov, V.
N.; Hell, S. W. Polar Red-Emitting Rhodamine Dyes with Reactive Groups: Synthesis,
Photophysical Properties, and Two-Color STED Nanoscopy Applications. Chemistry – A
European Journal 2013, 20 (1), 146–157.
(55) Keppler, A.; Kindermann, M.; Gendreizig, S.; Pick, H.; Vogel, H.; Johnsson, K. Labeling
of Fusion Proteins of O6-Alkylguanine-DNA Alkyltransferase with Small Molecules in
Vivo and in Vitro. Methods 2004, 32 (4), 437–444.
(56) Brown, J. M.; Wilson, W. R. Exploiting Tumour Hypoxia in Cancer Treatment. Nat Rev
Cancer 2004, 4 (6), 437–447.
(57) Wilson, W. R.; Hay, M. P. Targeting Hypoxia in Cancer Therapy. Nat Rev Cancer 2011,
11 (6), 393–410.
(58) Imai, T.; Horiuchi, A.; Wang, C.; Oka, K.; Ohira, S.; Nikaido, T.; Konishi, I. Hypoxia
Attenuates the Expression of E-Cadherin via Up-Regulation of SNAIL in Ovarian
Carcinoma Cells. The American Journal of Pathology 2003, 163 (4), 1437–1447.
(59) Singh, K.; Rotaru, A. M.; Beharry, A. A. Fluorescent Chemosensors as Future Tools for
Cancer Biology. ACS Chem. Biol. 2018, 13 (7), 1785–1798.
(60) Chevalier, A.; Zhang, Y.; Khdour, O. M.; Kaye, J. B.; Hecht, S. M. Mitochondrial
Nitroreductase Activity Enables Selective Imaging and Therapeutic Targeting. J. Am.
Chem. Soc. 2016, 138 (37), 12009–12012.
(61) Li, Z.; Li, X.; Gao, X.; Zhang, Y.; Shi, W.; Ma, H. Nitroreductase Detection and Hypoxic
Tumor Cell Imaging by a Designed Sensitive and Selective Fluorescent Probe, 7-[(5-
Nitrofuran-2-Yl)Methoxy]-3H-Phenoxazin-3-One. Anal. Chem. 2013, 85 (8), 3926–3932.
(62) Henderson, B. W.; Fingar, V. H. Relationship of Tumor Hypoxia and Response to
Photodynamic Treatment in an Experimental Mouse Tumor. Cancer Res 1987, 47 (12),
3110.
(63) Piao, W.; Hanaoka, K.; Fujisawa, T.; Takeuchi, S.; Komatsu, T.; Ueno, T.; Terai, T.;
Tahara, T.; Nagano, T.; Urano, Y. Development of an Azo-Based Photosensitizer
Activated under Mild Hypoxia for Photodynamic Therapy. J. Am. Chem. Soc. 2017, 139
(39), 13713–13719.
(64) Kiesslich, T.; Gollmer, A.; Maisch, T.; Berneburg, M.; Plaetzer, K. A Comprehensive
Tutorial on In Vitro Characterization of New Photosensitizers for Photodynamic
77
Antitumor Therapy and Photodynamic Inactivation of Microorganisms. BioMed Research
International 2013, 2013, 17.
(65) Gomes, A.; Fernandes, E.; Lima, J. L. F. C. Fluorescence Probes Used for Detection of
Reactive Oxygen Species. Journal of Biochemical and Biophysical Methods 2005, 65 (2),
45–80.
(66) Mark Wainwright. Natural Product Photosensitisers. In Photosensitisers in Biomedicine;
Wiley-Blackwell, 2009; pp 191–210.
(67) Zou, Q.; Fang, Y.; Zhao, Y.; Zhao, H.; Wang, Y.; Gu, Y.; Wu, F. Synthesis and in Vitro
Photocytotoxicity of Coumarin Derivatives for One- and Two-Photon Excited
Photodynamic Therapy. J. Med. Chem. 2013, 56 (13), 5288–5294.
(68) Dichiara, M.; Prezzavento, O.; Marrazzo, A.; Pittalà, V.; Salerno, L.; Rescifina, A.;
Amata, E. Recent Advances in Drug Discovery of Phototherapeutic Non-Porphyrinic
Anticancer Agents. European Journal of Medicinal Chemistry 2017, 142, 459–485.
(69) R.M. Herbst; D. Shemin. Acetylglycine. Org. Synth. 1939, 19 (4).
(70) Kudale, A. A.; Kendall, J.; Warford, C. C.; Wilkins, N. D.; Bodwell, G. J. Hydrolysis-Free
Synthesis of 3-Aminocoumarins. Tetrahedron Letters 2007, 48 (29), 5077–5080.
(71) Das, D. K.; Sarkar, S.; Khan, M.; Belal, M.; Khan, A. T. A Mild and Efficient Method for
Large Scale Synthesis of 3-Aminocoumarins and Its Further Application for the
Preparation of 4-Bromo-3-Aminocoumarins. Tetrahedron Letters 2014, 55 (35), 4869–
4874.
(72) Sigma-Aldrich. N-Acetylglycine
https://www.sigmaaldrich.com/catalog/product/aldrich/a16300?lang=en®ion=CA.
(73) Marazzi, M.; Besancenot, V.; Gattuso, H.; Lassalle, H.-P.; Grandemange, S.; Monari, A.
Photophysics of the Singlet Oxygen Sensor Green Chromophore: Self-Production of 1O2
Explained by Molecular Modeling. J. Phys. Chem. B 2017, 121 (32), 7586–7592.
(74) Subba Rao, R. V.; Krishnamurthy, M.; Dogra, S. K. Fluorescence Spectra of 3-
Aminocoumarin and Its Acid—Base Behaviour in the Excited Singlet State. Journal of
Photochemistry 1986, 34 (1), 55–61.
78
Appendix A: NMR & Mass Spectrum of Synthesized Compounds
Figure S1. 1H-NMR of guanine salt in DMSO-d6.
79
Figure S2. 1H-NMR of Alkyne O6 Benzyl Guanine in DMSO-d6.
80
Figure S3. 1H-NMR of Alkyne O6 Benzyl Guanine N9 Propylamine BHQ2 in DMSO-d6.
81
Figure S4. 1H-NMR of 3-azidopropan-1-ol in CDCl3.
82
Figure S5. 1H-NMR of 3-azido-N-methylpropan-1-amine in CDCl3. Note, the oil was contaminated with THF and TEA.
83
Figure S6. 1H-NMR of CF3 protected 4-methylamine benzyl alcohol in CDCl3.
84
Figure S7. 1H-NMR of CF3 protected 4-methylamine O6 benzyl guanine in DMSO-d6.
85
Figure S8. 1H-NMR of N-acetylglycine in DMSO-d6.
86
Figure S9. 1H-NMR of 3AIC-Acetate in DMSO-d6.
H2
O
DMSO-
d6
87
Figure S10. 1H-NMR of 3AIC in CDCl3.
CDCl3
88
Figure S11. ESI- mass spectrum of RB-N3 dissolved in methanol.
89
Figure S12. ESI- mass spectrum of probe 1 (P1) dissolved in methanol.
90
Figure S13. ESI+/ESI- mass spectrum of Sarcosine linked pyro A dissolved in methanol.
91
Figure S14. ESI+ mass spectrum of probe 1 no quencher (P1NQ) dissolved in methanol.
92
Figure S15. ESI+ mass spectrum of p-NBMB dissolved in methanol.